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Abstract 
 
Inflammatory Bowel Disease (IBD) affects approximately one in five hundred inhabitants, in 
the Western world. Since conventional treatment is harsh and not curative, growing attention 
has been given to probiotics as a safe alternative. Probiotics are live microorganisms with a 
beneficial effect on the host by improving the intestinal microbial balance. We have 
performed a literature search of clinical trials involving probiotics treatment of IBD with 
focus on Crohn’s Disease (CD) and Ulcerative Colitis (UC). We found that several probiotics 
(E. coli Nissle 1917, BIFICO, BFM, VSL#3, Trichuris suis and LGG) showed efficacy in 
maintaining remission in UC, but not in CD.  
 
We also evaluated the literature on probiotics and their mechanisms of action. We describe 
how animal models show probiotics to 1) inhibit microbial pathogens growth 2) increase 
epithelial barrier function and 3) modulate the immune response of intestinal epithelia and 
mucosal immune cells. This seem to support the “hygiene hypothesis” claiming that modern 
lifestyle is too sterile, whereby the immune system does not develop properly thus causing 
IBD in predisposed individuals. 
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Abbreviations 
AP-1: Activator protein 1 
CAMPs: Cationic antimicrobial peptides 
CARD: Caspase activating recruitment domain  
CD: Crohn’s disease  
CD40: Cluster of difference 40 
COX-2: Cyclooxygenase-2 
DCs: Dendritis cells  
FAE: Follicle-associated epithelium 
GALT: Gut-associated lympoid tissue  
GI: Gastrointestinal tract  
HLA: Human leukocyte antigen 
IBD: Inflammatory Bowel Disease  
ICAM-1: Intercellular adhesion molecule  
IgA: Immunoglobulin A  
IkB: Inhibitor of kB 
IKK: Inhibitor of kB kinase  
IL: Interleukin 
ILF: Isolated lymphoid follicle  
INF-α: Interferon-alpha 
iNOS: Inducible NO synthase  
IRAK4: IL-1 receptor-associated kinase-4  
IRF: Interferon regulatory factor 
JNK: c-Jun N-terminal kinase 
LPS: Lipopolysaccharide 
LRR: Leucine-rich repeat  
M cells: Microfold cells 
Mal: Myd88-adaptor-like 
MALT: Mucosa-associated lymphoid tissue 
MAPK: Mitogen-activated protein kinase  
MEKK: Mitogen-activated protein kinase kinase  
MHC: Major histocompatability complex 
MyD88: Myeloid differentiation primary-
response protein 88 
NF-kB: Nuclear factor kB 
NOD: Nucleotide oligomerization domain 
OCTN: Organic cation/carnitine transporters 
PAMP: Pathogen-associated molecular patterns 
PPAR-g: Peroxisome proliferative activated 
receptor-g 
PRR: Pattern recognition receptors 
RelA/RelB/c-Rel 
RIP1: Receptor-interacting protein 1 
RIP2 or RICK: Receptor-interacting protein 2 
SAA: Serum amyloid A 
SCID: Severe Combined Immunodificiency 
SED: Subepithelial dome 
SIGIRR: Single immunoglobulin IL-1R-related 
protein 
TAK1: Transforming growth factor-b-activated 
kinase-1 
TCR: T-cell receptor 
TGF-b: Transforming growth factor-b 
TH1: T helper 1 
TH2: T helper 2  
TICAM2: TIR-containing adaptor molecule-2 
TIR: Toll-IL-1 receptor 
TLR: Toll-like receptor 
TNF: Tumor necrosis factor 
TOLLIP: Toll-interacting protein  
TRAF6: Tumor necrosis tactor receptor 
associated factor-6 
TRAM : TRIF-related adaptor molecule 
TRIF: TIR-containing adaptor inducing IFN-b 
Ub-TRAF: Ubiquitinated TRAF6   
UC: Ulcerative colitis 
VCAM-1: Vascular cell adhesion molecule 
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1. Introduction 
 
Inflammatory Bowel Disease (IBD) is a group of chronic diseases confined to the 
gastrointestinal system, characterised by periods of active disease interrupted by periods of 
remission without symptoms. Crohn’s disease (CD) and ulcerative colitis (UC) are the two 
major forms. The two diseases have different etiology and location in the gut; UC is confined 
to the colon whereas CD can be located in both the small and large intestine. In Denmark 
there are approximately 8,000 patients with UC (~450 new cases per year) and there are 
approximately 6,000 patients with CD (~350 new cases per year). This frequency of roughly 
1/500 persons is found in most of the Western world with third world countries catching up as 
they adopt a Western lifestyle. The pathogenesis of IBD is not fully understood; numerous 
theories exists that blame factors such as modern day hygiene and various dietary factors that 
supposedly play a modulating role in the disease process. It is believed that IBD is caused by 
an overly aggressive acquired active immune (T cell) response, in genetically disposed 
individuals as a response to certain bacteria among the gut flora as well as environmental 
factors.  
 
Figure 1 Factors believed to be contributing to the development of IBD. A subset of commensal bacteria induces 
an immune response in genetically susceptible individuals. Environmental factors are also thought to contribute 
to the disease development (figure adapted from Sartor, 2006). (Sartor, 2006) 
 
At the beginning of the 20th century the Russian Nobel prize winner Elie Metchnikoff 
hypothesized that consummation of fermenting bacteria in dairy products by Bulgarian 
peasants were responsible for their longevity. In 1965 D. Lily and R. Stillwell introduced the 
Commensal bacteria
Genetic susceptibility
Enviromental triggers
Immune responseIBD
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term probiotics as an antagonist to the word antibiotics. And since the 1970s, probiotics have 
been applied as an alternative treatment.   
Today probiotics appear as a promising dietary factor that can be used as a complementary 
therapy in the treatment of IBD. Probiotics are defined as a live microbial feed supplement 
that beneficially affects the host by improving the intestinal microbial balance. 
The idea of replacing or supporting human intestinal gut flora is likely to have been inspired 
by the beneficial digestive effects attributed to the ingestion of cultured foods such as diary 
products. Several different microorganisms including bacteria, fungi and whipworms have 
been applied in trials and proposed for treatments of IBD, but most commonly therapies are 
based on lactic acid producing bacteria such as Lactobacillus, streptococcus, Lactococcus, 
Bifidobacterium, Escherichia  coli Nissle 1917 and the yeast Saccharomyces boulardii. 
 
A greater understanding of the mechanisms behind probiotic action on the gastrointestinal 
microflora is required in order to determine, which probiotic are the most beneficial. The 
beneficial mechanisms of probiotics are currently thought to be one or more of the following: 
production of various antimicrobial metabolites, competitive exclusion of enteric pathogens, 
neutralization of dietary carcinogens, and modulation of mucosal immune 
responses.(Rachmilewitz et al., 2004). The beneficial effect of probiotics has been 
demonstrated mainly in the prevention and treatment of pouchitis and in maintaining 
remission of mild to moderate ulcerative colitis. Probiotic treatment seems to have less effect 
in patients with Crohn's disease. 
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2. The aim of the project  
 
Which current evidence supports the use of probiotics for the clinical treatment of 
Inflammatory Bowel Disease?  
 
Treatment of inflammatory bowel disease (IBD) usually involves the use of 
immunosuppressive drugs, which are associated with adverse side effects, and in severe cases 
even surgery. Novel treatments of IBD with probiotics as a substitute or complement to 
conventional drugs are receiving growing attention.  
Through a review of current literature and controlled clinical studies of patients with IBD, we 
will describe the effects of probiotics on gastrointestinal physiology and patophysiology and 
present the theoretical basis of using probiotics in treatment of IBD. Finally we will present 
suggestions for future clinical trials and discuss whether probiotics should be viewed as an 
alternative treatment or a supplement.  
 12
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3. Pathology of Inflammatory Bowel Diseases  
Inflammatory Bowel Diseases (IBD) consists primarily of the two diseases, Crohn’s Diseases 
(CD) and ulcerative colitis (UC). The diseases are caused by inflammation in the 
gastrointestinal tract, but the exact etiology is unknown. Even CD and UC both have common 
features as inflammation in the bowel, genetic factors, dysregulated immune system, and 
almost similar symptoms such as abdominal pain and diarrhoea, but still they have there own 
distinguishing (Neuman, 2007).  
Patients with IBD are characterized by a defective immune response leading to inflammation 
and tissue damage. The immune system opposes the bacteria that are normally found in 
intestines, leading to an immunological imbalance. Both CD and UC are characterized by a 
TH1 profile (see section 6.12). Medical treatment is not curative but aims at ameliorating the 
symptoms, obtaining and preserving remission (Viscido et al., 2005; Sartor, 2006). 
 
3.1 Crohn’s disease  
Annually there are 10 new incidences of CD per 100,000 inhabitants, in Denmark. There are 
several different types of the disease; depending on the affected area of the gut. In 
approximately fifty percent of cases the Ileocolic Crohn's Disease is located in the ileum and 
in the large intestine. Crohn's ileitis affecting the ileum only is seen in approximately thirty 
percent all of patients and in the remaining cases Crohn's colitis, which affects the large 
intestine alone. However combinations of the three diagnoses are seen, where the entire gut is 
affected. CD affect the submucosal layer to a greater extent than the mucosal layer; a 
characteristic feature of CD is the demarcated granulomatous lesions that are surrounded by 
normal-appearing mucosal tissue that leads to an inflamed bowel surface as cobblestone 
appearance (Fig. 2A)        
The primary symptoms in CD are intermittent diarrhea, coliclypain, weigt loss, fluid and 
electrolyte disorders, malaise, and low-grade fever. Complications of CD include narrowing 
of the bowel, which may lead to bowel obstruction, abnormal passageways (fistulae) between 
the bowel and other structures such as the skin, which may lead to surgery. 
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To diagnose CD, sigmoidoscopy is used to visualize the affected areas and to obtain biopsies, 
and CT-scan to detect an inflammatory mass or abscess. Medical treatment methods to 
promoting the healing are also used (see chapter 4 for details on treatment) (Porth, 2007). 
  
3.2 Ulcerative Colitis  
Annually there are 17 incidences of UC per 100.000 inhabitants, in Denmark. UC affects the 
large intestine with ulcers or open sores. The inflammation can format to large areas and give 
very big ulceration (Fig. 2B). There are several different known forms of UC: 
Proctosigmoiditis colitis affecting the rectum and the sigmoid colon. Left-sided colitis is 
characterized by continuous inflammation beginning at the rectum and extending as far as the 
splenic flexure and Pan-ulcerative colitis affecting the entire colon. The primary symptoms 
in UC are diarrhoea, 30 to 40 bowel movements a day. UC affects the mucosal layer of the 
bowel, and the stools contain blood and mucus. The severity of the disease varies from mild 
to fulminating, the disease has been divided into three types: mild chronic, chronic 
intermittent, and acute fulminating. The common form is the mild chronic, in which the 
symptoms as diarrhoea and bleeding are in mild form. This form can be cured, when the 
others gives complication. Cancer of the colon is one of the feared complications. 
The diagnosis usually is confirmed by proctosigmoidoscopy. Medical treatments are similar 
to those used in CD (Porth, 2007). 
 
 
Figure 2 A: Crohn’s disease. B: Ulcerative colitis. UC can be distinguished from CD by the large unbroken area 
with inflammation, and the localization of the inflammation to the upper layer of the mucosa. CD shows a more 
broken pattern of inflammation (pictures from Porth, 2007). 
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4. Conventional treatment of IBD 
 
The conventional drugs used for treating IBD are: aminosalicylates, corticosteroids, TNF-α 
antibodies, immunosuppressants, antimicrobials and surgery. They are rather effective but not 
curative. They are used to obtain remission and maintaining remission. The drugs used for 
treating UC and CD are broadly the same but different response occurs. The drugs will be 
described below. 
 
4.1 Aminosalicylates 
These drugs are used to treat mild to moderate active IBD, and for achieving and maintaining 
remission. There is seen a better respond of the treatment with aminosalicylates in patients 
with UC than in patients with CD.  
 
The active therapeutic component of aminosalicylates is mesalazine (also known as 
mesalamine; 5-aminosalicylic acid (5-ASA)). The mechanisms of action of mesalazine are 
still unknown, but it may involve reduced cytokine formation by inhibition of leukocyte 
chemotaxi, reduced free radical generation and inhibition of the production of inflammatory 
mediators such as prostaglandin and leukotrienes. It may also function as a peroxisome 
proliferative activated receptor-γ (PPAR-γ) agonist, decreases the activation of interleukin 1 
(IL-1) and tumour necrosis factor (TNF), induces apoptosis and act as a weak inhibitor of 
nuclear factor κB  (NFκB) activity.  
 
Mesalazine is usually well tolerated and has no serious side effect. The side effect is dose 
dependent and patients may experience headache, nausea, vomiting and diarrhoea (Nielsen 
and Munck, 2007) (Waller et al., 2005). 
 
4.2 Corticosteroids 
Corticosteroids are used to patient with sever active IBD or to patient where aminosalicylates 
are ineffective. Corticosteroids are only used to induce remission because of the significant 
side effects such as elevated blood pressure, glaucoma, osteoporosis, mood swings and 
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anxiety. Once remission is obtained aminosalicylates or immunosuppressants drugs must be 
used to maintain remission.  
The immunomodulatory actions of corticosteroids are probably due to the inhibition of pro-
inflammatory transcription factors such as activator protein 1 (AP-1) and NFκB (Waller et al., 
2005). 
 
4.3 TNF-α antibodies 
Infliximab is a monoclonal antibody. It is used to induce remission in both UC and CD and it 
can obtain remission up to 3 month.  
 
TNF-α is an important cause of inflammation in CD and infliximab inhibits the binding of 
TNF-α to its receptors. This probably reduces the production of pro-inflammatory cytokines 
IL-1 and IL-6, leukocyte migration and infiltration and eosinophil and neutrophil activation. 
 
About 15% of patients given infliximab experiences side effects as fever, chills, pruritis or 
urticaria. Another problem is the formation of antibody with may cause allergic reactions 
and/or loss of efficacy (Waller et al., 2005). 
 
4.4 Immunosuppressants 
The most used immunosuppressants in IBD are azathioprine and 6-mercaptopurine. They take 
12 to 16 weeks to work because they suppress the bone marrow and as a result the immune 
response. They are used as second-line drugs once remission has been induced by another 
medication. They can also help patients to get free of corticosteroids treatment. Side effect 
such as nausea, vomiting, skin rashes and a hypersensitivity syndrome effects 10 % of the 
patient during the first 6 weeks.  
Potential side effect as liver problems or pancreatitis is rare and frequent monitoring is 
recommended due to this side effects (Waller et al., 2005).  
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4.5 Antimicrobials 
Metronidazole can be moderately effective in treating perineal CD and after ileum resection. 
They are often used in combination with other medical treatment. The mechanisms of action 
are unknown. Side effect such as nausea, vomiting, metallic tastes, rashes and intolerance to 
alcohol can occur (Waller et al., 2005). 
 
4.6 Surgery 
More than 15 % of all UC patients and 50 % of all CD patients will receive surgical treatment 
at some point (Marteau et al., 2006). 
 
Surgery for UC is performed to keep patient symptom free and it is also recommended 
because of the high risk of cancer in infected tissue. A colectomy or an ileal-anal pouch 
surgery is performed, which is the removal of the entire colon and rectum. Colectomy is 
where an end-ileostomy is created on the lower abdomen outside of the patients’ body. The 
patients have to wear a small bag where the chyme is collected. An ileal-anal pouch surgery is 
where the small intestine is attached to the anus and the patient can defecate normally 
afterwards. But there may be up to seven watery bowel movements a day because the colon is 
not there to absorb water1. 
 
Surgery for CD is performed for several reasons; the medical therapy does not control the 
patients’ symptoms or developed complications such as blockage, abscess, perforation or 
bleeding into the intestine. Resection is the surgery used to CD where the diseased part of the 
intestine is removed. Symptoms may return after surgery2. 
 
 
 
 
 
 
                                                 
1 Mayo Clinic: http://www.mayoclinic.org/ulcerative-colitis/treatment.html (on the internet May 25 - 2007). 
2 Mayo Clinic: http://www.mayoclinic.org/crohns/surgery.html (on the internet May 25 – 2007). 
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5. Genetic factors of IBD 
 
IBD is a multifactorial disease since both genetic factors as well as environmental factors 
such as smoking habits and the nature of gut flora seems to underlie the pathophysiology of 
IBD. But a positive familial history of IBD is the most well established risk factor for 
development of IBD. Children whom have parents that are both suffering from IBD have an 
estimated 33% risk of developing IBD themselves before the age of 28. Furthermore 
individuals who have relatives with Crohn’s disease are subjected to not only higher risk of 
Crohn’s development but also to development of ulcerative colitis. Several susceptibility 
genes have been indicated and it has been proposed that Crohn’s and UC are both polygenic 
diseases sharing some of the same susceptibility genes. With the use of genome-wide scans 
several loci termed IBD1-8 have been associated with IBD. Genome-wide scans mediate the 
finding of candidate genes. Genetic variation of candidate genes might provide clues to the 
molecular function or dysfunction of specific proteins (Russell et al., 2004).  
 
IBD1 locus is found in the centromere of chromosome 16 and contains the gene for 
NOD2/CARD15 (see section 6.10). Three polymorphisms of this gene have been associated 
with the onset of Crohn’s disease. Two missense mutations Arg702Trp and Gly908Arg and 
one frameshift mutation Leu1007fsincC. The frameshift mutations introduces a premature 
stop codon, leading to a truncated protein (Russell et al., 2004). Two of these polymorphisms 
are located in the LRR domain and the latter upstream of this, but all three of them results in 
reduced NF-κB activity. NOD2/CARD15 promotes expression of cytokines and thereby 
inflammation. But studies however have demonstrated that NOD2 is able to negatively 
regulate TLR9 responses while positively regulating other TLR responses. NOD mRNA is 
found mainly in Paneth cells, which are mostly concentrated in the ileum. This could be a 
explanation to the observed linkage of NOD2 mutations with Crohn’s disease (Watanabe et 
al., 2005). 
 
IBD2 is a locus associated with susceptibility to ulcerative colitis only. No candidate genes 
have been found yet though (Russell et al., 2004)..  
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IBD3 is located on chromosome 6 and surrounds the major histocompatability complex 
(MHC), which is a gene region that plays a role in the immune system. A subset of genes in 
MHC is the human leukocyte antigen (HLA) genes, which encodes the MHC class I and II 
proteins. An HLA allele called HLADRB1*1030 has been associated with ulcerative colitis. 
Mutations in the promoter region of the gene encoding TNF-α, which is also located in IBD3 
locus, have also been linked to susceptibility to IBD (Russell et al., 2004). 
 
IBD4 locus is located in chromosome 14 and has been linked to susceptibility to Crohn’s 
disease.  
 
IDB5 region is located in chromosome 5 and contains a cluster of genes coding for cytokines, 
which have been associated with the development of Crohn’s disease (Russell et al., 2004). 
This region also contains a cluster of genes encoding for organic cation/carnitine transporters 
called OCTN1 and OCTN2. Gene alleles SCL22A4 and SCL22A5 coding for OCTN1 and 
OCTN2 respectively are associated with susceptibility to Crohn’s disease. The carnitine 
transporters OCTN1 and 2 transport acyl-Carnitine across the inner membrane of 
mitochondria. The polar zwitterion l-Carnitine therefore has an important role in the transport 
of long-chain fatty acids into mitochondria for subsequent β-oxidation. OCTN1 and 2, which 
is also found in intestinal therefore has a role in epithelia bioenergetic metabolism. In rat 
colonic mucosa it has been demonstrated that inhibition of β-oxidation could cause ulceration, 
destruction of mucus cells and acute colitis. It is therefore suggested that a mutation leading to 
dysfunction of OCTN1 and 2 could lead to Crohn’s disease. Interestingly it has been 
demonstrated that a specific mutation Leu503Phe in OCTN1 leads to an 6-9 amino acids 
antigenic determinant/epitope shared with two bacteria Campylobacter jejuni and 
Mycobacterium paratuberculosis both known to be implicated in development of IBD. It is 
therefore thought that infection by one of those pathogens could lead to production of 
antibodies, which could cross-react with the already dysfunctional OCTN1 causing further 
harm (Lamhonwah et al., 2005).    
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6. Intestinal immunity 
 
The gastrointestinal lining presents the largest surface area exposed to the outside 
environment. Most pathogens enter the human organism through the mucus membrane of this 
lining. The intestinal immune system is though not only obligated to protect against these 
pathogens, but also to ensure homeostasis with the more than 1014 commensal bacteria of the 
intestine.  
 
The intestinal epithelia cells are joined together by tight junctions forming a physical barrier. 
The apical surface of the epithelia is covered by mucus produced by goblet cells and a 
network of polysaccharide called glycocalyx. The main protein component of mucus is a 
glycosylated macromolecule called mucin functions together with the glycocalyx to trap both 
pathogens and commensal bacteria. Other components of the mucus are cationic antimicrobial 
peptides (CAMPs) such as defensins and immunoglobulin A (IgA) both aiding in protection 
against pathogens. Most commensal bacteria reside on the luminal side of the mucus layer, 
and one of the main features distinguishing commensal bacteria from pathogens, is the ability 
to gain access to and penetrate the apical surface of the epithelia. But some commensal 
bacteria are able to reach the epithelia and modify the immunity of the intestines to benefit of 
the host as will be discussed later (Magalhaes et al., 2007). 
  
 
The intestinal epithelia not only function as a physical barrier but also - in conjunction with 
the mucosa-associated lymphoid tissue (MALT) - as an inducer of innate and adaptive 
immunity. MALT is the largest lymphoid structure in the human organism and is subdivided 
in to the gut-associated lymphoid tissue (GALT), which is associated with the gastrointestinal 
tract. GALT again can be divided into inductive sites where antigens are sensed and immunity 
induced, and the effector sites where especially lymphocytes differentiate and mediate their 
response (Magalhaes et al., 2007).   
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6.1 Inductor sites of GALT  
The follicle-associated epithelium (FAE) is mostly found in ileum of small intestine covering 
the Peyers patches but is also found in the colonic patches (not shown in figure 3) of the colon 
and in the remaining GI covering isolated lymphoid follicle (ILF). FAE contains microfold 
cells (M cells), which captures soluble antigens, bacteria and Toll-like receptor ligands (se 
next section) from the lumen. M cells transport theses substances by transcytosis in a toll-like 
receptor dependent manner (Tyrer et al., 2006) to the subepithelial dome (SED), which is part 
of Peyers patch or colonic patches and presents them to dedritic cells (DCs) or macrophages 
in the SED. Macrophages facilitates destruction of the foreign substances while DCs have 
toll-like receptors that recognizes toll-like receptor ligands and as a response turns on 
expression of cytokines.  
 
These cytokines can determine whether naïve Helper T cells of the underlying Peyers patch or 
colonic patch differentiates into T helper 1 (TH1), T helper 2 (TH2) or T regulatory cells (for 
more details regarding activation and differentiation of naïve T helper cells see the section 
“TH1 or TH2 response”). Peyers patches, colonic patches, mesenteric lymph nodes and ILF all 
have T cells, which mediate adaptive immunity in response to antigen-presentation mainly by 
DCs. T cells in return can active B cells also resident in these immune compartments 
(Magalhaes et al., 2007).   
 
6.2 Effector sites of GALT 
The effector compartment of GALT includes the epithelium and underlying lamina propria. 
The epithelium harbours intraepithelial lymphocytes, which detect damage to the epithelia. 
The lamina propria contains IgA secreting plasmocytes, T cells, B cells, macrophages, and 
DCs. DCs of the lamina propria extend their dendrites through the tight junctions of epithelial 
cells and captures pathogens of the lumen. DCs then migrate to the inductor sites and induces 
immune response (Magalhaes et al., 2007).    
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Figure 3 Immune defences against commensal intestinal bacteria. Commensal bacteria are present in large 
numbers outside the mucus layer. Bacteria that are able to penetrate the epithelial cell layer are quickly killed by 
macrophages in lamina propria. In Peyer’s patches bacteria are taken up by dendritic cells (DCs) and presented 
to B and T cells (see also section 6.12). After activation in the mesenteric lymph B and T cells travel to the 
thoracic duct were they enter the bloodstream and return back to the intestinal mucosa (figure adapted from 
Macpherson and Harris, 2004). 
  
In the following section will be given a detailed explanation on how enterocytes and cells 
such as DCs, neutrophils and macrophages detect pathogens and subsequently induce immune 
responses. The particulars may seem excessive, but are a necessity in order to understand the 
underlying genetics of IDB, the pathogenicity of pathogens and to appreciate the complex and 
beneficial effect of probiotics.   
 
6.3 Pattern recognition receptors 
At all times the GI is exposed to an immense number of microbes, both pathogens and 
nonpathogens. In order to sense these microbes’ epithelial cells as well as macrophages and 
neutrophils has specific receptors called pattern recognition receptors (PRR) recognizing 
different patterns of molecules mostly on the surface of these microbes. The molecules 
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recognized are different from those of the host, whereby the host’s innate immune system can 
recognize self from nonself.  
6.4 Toll-like receptors 
Toll-like receptors (TLR) are all type I transmembrane proteins of the Interleukin-1 receptor 
(IL-1R) family (West et al., 2006) and is an ancient type of PRR. The first of its kind to be 
identified was Drosophila Toll receptor a protein involved in dorso-ventral polarity of 
embryo. All multicellular organisms’ posses toll or TLR involved in innate immunity. In 
plants TLR receptors are involved in defence against fungus, bacteria and virus. The common 
ancestry of TLR’s suggests that these receptors evolved prior to the divergence of plants and 
animals more than a billion years ago. This long term conservation indicates that TLR has a 
very important role in innate immunity (Alberts et al., 2002).   
 
Human’s posses ten types of TLR (TLR1-10). All of them are receptors with a large 
extracellular domain consisting of leucine-rich repeats known as LRR motif and an 
intracellular signaling domain termed Toll-IL-1 receptor (TIR). TLR1, TLR2 and TRL4 
resides in the membrane apex of epithelia cells facing to GI lumen, whereas TLR5 is located 
at the basolateral membrane. TLR3, TLR7, TLR8 and TLR9 resides in the membrane of 
endosomes (Magalhaes et al., 2007).  
 
Toll-like receptors recognizes molecular patterns on pathogens known as pathogen-associated 
molecular patterns (PAMP) or pathogen-associated immunostimulants and molecular patterns 
of nonpathogens known as commensal-associated molecular patterns (CAMP). There is a 
great overlap of PAMP and CAMP since pathogen molecular patterns are also shared with 
nonpathogens. Different TLR in general recognizes different ligands thereby initiating a 
signal pathway, which ultimately leads to the production of general inflammatory mediators 
as well as an appropriate response to the specific type of pathogen. Some TLR though may 
bind to several different ligands (Kalliomäki and Walker, 2005). And furthermore different 
TLRs may heterodimerize to increase the diversity of recognized ligands and perhaps also 
increasing to diversity of signal pathways induced (West et al., 2006) Some of the most 
significant ligands appears from table 1. Some ligands such a teichoic acids are specific for 
gram-positive bacteria, others like lipopolysaccharide (LPS) are specific for gram-negative 
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bacteria, and some are present in both bacteria types such as peptydoglycan, formylated 
methionine and CpG DNA motif. The N-terminal amino acid in eukaryotes is a methionine 
whereas it is a formylated methionine in prokaryotes. CpG motif is an unmethylated 
dinucleotide, which is twenty times less common in vertebrate DNA than in bacterial DNA. 
Fungi have ligands such as zymosan, glucan and chitin. Many parasites has ligands, among 
them Plasmodium which has glycosylphosphatidylinositol on its surface (Alberts et al., 2002).  
 
Pattern recognition receptor  Ligand 
TLR1 Bacterial lipopeptides 
TLR2 Bacterial cell wall lipoteichaic acid, lipoproteins 
TLR3 Bacterial cell wall peptidoglycan, double-stranded RNA 
TLR4 Bacterial lipopolysaccharide 
TLR5 Bacterial flagellin 
TLR6 Diacylated and triacylated bacterial lipopeptides 
TLR7 Guanosine-rich and uridine-rich single-stranded viral RNA 
TLR8 Guanosine-rich and uridine-rich single-stranded viral RNA 
TLR9 Bacterial and viral DNA 
TLR10 Not known 
Nod1 GM-tri-DAP (mesodiaminopimelate-containing N-
acetylglucosamin-N-acetyl-ramic acid tripeptide). A 
peptidoglycan hydrolysis product found in gram-negative 
bacteria and some gram-positive bacteria  
Nod2 Myramyl dipeptide in cell wall peptidoglycans from all 
bacteria 
Peptidoglycan recognition 
protein 
Bacterial peptidoglycan 
Table 1 Mammalian pattern recognition receptors and their ligands 
 
6.5 NOD receptors 
Other pattern recognition receptors are the soluble receptors of the complement, which resides 
in the blood. And still others are nucleotide oligomerization domain 1 (NOD1) and nucleotide 
oligomerization domain 2 (NOD2) receptors, which are found in the cytosol of intestinal 
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epithelia. These receptors have been renamed to caspase activating recruitment domain 4 
(CARD4) and caspase activating recruitment domain 15 (CARD15) respectively.        
 
Figure 4 Pattern recognition receptors and their typical ligands. TLRs 1/2/6, 4 and 5 are located on the surface of 
most cells, whereas TLRs 3, 7-9 are located in endosomes in the cytosol. Signals through TLRs 1/2/6, 5, 7-9 are 
mediated exclusively by MyD88 leading to NF-κB and AP-1 activation. TLRs 3 and 4 also utilize MyD88-
independent signalling leading to NF-κB and IRF-3 activation. NOD1 and NOD2 are located in the cytoplasm 
and activate NF-κB (figure adapted from Kalliomäki and Walker, 2005).  
 
6.6 Signal transduction 
PAMPs activate TLRs in two different manners. PAMP binding to TLR causes dimerization 
of the receptors and induces structural conformation change of cytoplasmic TLR domain, 
which faciliates binding of adaptor proteins, or preformed dimers binds PAMP thereby 
leading to conformation change and subsequent recruitment of adaptor proteins (West et al., 
2006). The intracellular domain of different toll-like receptors TIR, transduces signals from 
the extracellular domain to intracellular signal proteins thereby activating different signal 
pathways, myeloid differentiation primary-response protein 88 (MyD88)-dependent pathway 
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and/or MyD88-independent signal pathway. Eventually the transduced signal activates the 
transcription factors nuclear factor (NF-κB), activator protein 1 (AP-1) and interferon 
regulatory factor 3 (IRF3).  As seen in figure 4, MyD88-dependent signal pathway activates 
NF-κB and AP-1 thereby initiating transcription of proinflammatory genes, whereas MyD88-
independent signal pathway activates NF-κB and IRF-3 thereby initiating transcription of 
proinflammatory genes and interferon beta (IFN-β) respectively. NOD1 and NOD2 leads to 
transcription of proinflammatory genes by activating NF-κB directly (Kalliomäki and Walker, 
2005).   
 
6.7 TLR signaling (MyD88-dependent signaling) 
TLR1, TLR2, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR11 signals through the adaptor 
protein MyD88 (see figure 5). MyD88 has a C-terminal TIR domain that in a homotypic 
manner interacts with the TIR domain of TLR and an N-terminal death domain that interacts 
with death domains of other proteins. TLR2 and TLR4 have an additional adaptor called TIR 
domain-containing adaptor protein (TIRAP) or Myd88-adaptor-like (Mal) that bridges TLR 
and MyD88. MyD88 interacts with the serine/threonine IL-1 receptor-associated kinase-4 
(IRAK-4) and IRAK-4 subsequently phophorylates IRAK-1, which again autophosphorylates 
itself and recruits tumour necrosis factor receptor associated factor-6 (TRAF).  Ultimately a 
Myd88/IRAK-4/IRAK-1/TRAF-6 complex is formed. TRAF6 is dimerized and binds to 
ubiquitin-conjugating enzyme 13 (UBC13) and a UBC-like protein (UEV1A), whereby 
TRAF6 itself is ubiquitinated. The ubiquitinated TRAF6 (Ub-TRAF6) dissociates from the 
complex and binds to another complex constituted by transforming growth factor-β-activated 
kinase-1 (TAK1) and two adaptor proteins, TGF-β binding protein-1 (TAB1) and TAB2 not 
shown in the figure. TAK1 is a MAPK kinase kinase (MAPKKK), which phophorylates 
MAPK kinase kinases (MAPKK) called MEKKs or another protein called NIK. The MEKKs 
and NIK are not shown in figure 5. MEKKs or NIK then phosphorylates a MAPK called p38 
and c-Jun N-terminal kinase (JNK). JNK then activates transcription factor AP-1 (Barton and 
Medzhitov, 2003).  
 
TAK1 complexed with a MEKK or NIK also phosphorylates and activates the β subunit of 
the inhibitor of κB kinase (IKK) complex. IKK then phosphorylates inhibitor of κB (IκB), 
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which leads to degradation of IκB by ubiquitin/proteasome system and thereby release of the 
NF-κB subunits p65 (Rel-a) and p50. When the p65/p50 heterodimer is released it 
translocates to the nucleus where it binds to the promoter or enhancer regions of immune 
genes such as tumour necrosis factor-α (TNF-α) (West et al., 2006).  
Myd88/IRAK-4/IRAK-1/TRAF-6 complex also activates the transcription factors interferon 
regulatory factor 5 (IRF5) and IRF7 leading to synthesis of cytokine and IFN-α. 
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Figure 5 NOD1/NOD2 and TLR4 signaling pathways. NOD1/NOD2 activates NF-κB through RICK and IKK. 
TLR4 utilizes both MyD88 and TRIF. MyD88 recruits IRAK-4 and IRAK-1, which then associates with TRAF6 
and ECSIT. TRAF6 then activates TAK-1, which in turn activates IKK, JNK and p38 eventually leading to NF-
κB and AP-1 activation. TRIF activates both RIP-1 and TBK-1 leading to activation of NF-κB, AP-1 and IRF-3. 
The activated transcription factors enter the nucleus and initiate the transcription of inflammatory genes (figure 
adapted from West et al., 2006). 
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6.8 TLR signaling (MyD88-independent signaling) 
TLR3 and TLR4 signals in a MyD88-independent manner (see figure 5). An adaptor called 
TRIF-related adaptor molecule (TRAM) or TIR-containing adaptor molecule-2 (TICAM-2) 
acts as a bridge in transducing signal from TLR3 to TRIF. It is not completely understood 
how TIR-containing adaptor inducing IFN-β (TRIF) activates the transcription factors NF-κB 
and IRF3. Some studies have suggested that TRIF interact directly with TRAF6 consequently 
activating NF-κB. Other studies suggests that TRIF interacts with receptor-interacting protein 
1 (RIP1) and that RIP1 actives TRAF6 ultimately activating NF-κB. TRIF also activates 
TRAF-family-member-associated NF-κB activator TANK-binding kinase (TBK-1), which 
phosphorylates IRF3. IRF3 phosphorylation leads to production of the cytokine interferon-β 
(IFN-β) (West et al., 2006). 
 
6.9 TLR Signal transduction inhibitors 
Excessive inflammation which can be very harmful to the host is regulated by inhibitors of 
TLR signal transduction. There are several inhibitors of TLR signal transduction pathways in 
enterocytes, macrophages, dendritic cells (DCs) e.g. some being transmembrane receptors 
others being cytoplasmic proteins. Among the transmembrane are the single immunoglobulin 
IL-1R-related protein (SIGIRR), which is thought recruited by TLR4 and inhibiting its signal 
pathway by sequestering IRAK-1 and TRAF6. ST2L likewise block TLR4 signaling by 
sequestering the adaptors MyD88 and TIRAP (West et al., 2006).  Others are the cytokine IL-
10 and transforming growth factor-β (TGF-β) (Kalliomäki and Walker, 2005). IL-10 executes 
its immunosupressive effect in multiples ways including suppression of protein translation, 
destabilization of mRNA and inhibition of gene transcription. For instance IL-10 is known to 
inhibit activation of NF-κB and the MAPK p38 thereby inhibiting TLR induced signal 
transduction. Consequently IL-10 inhibits production of proinflammatory cytokines and 
activation of macrophages and neutrophils (Weaver et al., 2007). More indirectly IL-10 is 
immunosupressive through induction of TGF-β secretion in lamina propria T cells. TGF-β 
mediates its effect by different signal cascades among them MAPK pathways. One effects of 
TGF-β is to induce degradation of TLR2 (Clavel and Haller, 2007).   
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The cytoplasmic inhibitors are IRAK-M found in monocytes and macrophages only and 
thought to interfere with the interaction of IRAK-1 and TRAF6. Supressor of cytokine 
signaling (SOCS-1) is thought either to block IRAK-1 activation or inhibiting TLR2 and 
TLR4 signaling by mediating degradation of the adaptor TIRAP. Toll-interacting protein 
(TOLLIP) inhibits TLR2 and TLR4 signaling by forming a complex with IRAK-1 thereby 
impeding its autophosphorylation (West et al., 2006). Other cytoplasmic inhibitors are the 
peroxisome proliferator activated receptor-γ (PPAR-γ) and the zinc finger protein A20 
(Kalliomäki and Walker, 2005). PPAR-γ is a nuclear receptor that promotes export of the 
RelA subunit of NF-κB from the nucleus to the cytosol and thereby attenuate the 
transcriptional activity of NF-κB.  
 
 
CYTOSOL
TLR
TIRAP
MyD88
IRAK-4
IRAK-1
TRAF6
ECSIT
UEV1A
UBC13
p50
p65
IκBIκB degraded
NF-κB
SOCS-1
TOLLIP
TIRAP
MyD88
IRAK-M
SIGIRR ST2L
Figure 6 TLR signal transduction inhibitors. TLR signalling can be dampened by negative regulators. TOLLIP, 
IRAK-M and SOCS-1 are cytoplasmic molecules that block IRAK-1 and thereby inhibit NF-κB activation. 
SIGIRR and ST2L are transmembrane receptors that inhibit TLR signalling by either blocking MyD88/IRAK-
4/IRAK-1 activation or by sequestering MyD88 (figure adapted from West et al., 2006). 
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6.10 NOD1/NOD2 signaling 
NOD1/CARD4 and NOD2/CARD15 are cytoplasmic receptors that recognize bacterial 
components through a LRR motif consistently with TLR receptors (see figure 5). At the N-
terminal these receptors have caspase activating recruitment domains that interacts with a 
serine threonine kinase termed receptor interacting protein-2 (Rip2) or RICK. Rip2 interacts 
with NFκB resulting in transcription of pro-inflammatory cytokines eventually and eventually 
activating innate immunity (Russell et al., 2004). 
 
6.11 NFκB response 
NFκB has overwhelming many target genes and therefore likewise many function in both 
innate and adaptive immunity. Therefore only a selection of implications will be discussed in 
this section. NFκB existing in almost all cell types comprises five members in mammalians, 
NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB, and c-Rel. NFκB protein forms different 
combinations of homo- and heterodimers each having a specific response corresponding to 
the type of invading pathogen. The complexes of p50/p65, p50/c-rel, p65/p65, and p65/c-rel 
are all transcriptionally active with p50/p65 being the most inducible, while p50 and p52 
homodimers are transcriptionally repressive. NFκB has several target genes expressing 
proteins such as the cytokines (e.g., IL-1, IL-2, IL-6, IL-12, TNF-α, LTα, LTβ, GM-CSF and 
INF-γ), adhesion molecules (e.g., intercellular adhesion molecule such as ICAM-1, vascular 
cell adhesion molecule such as VCAM-1, and endothelial leukocyte adhesion molecule such 
as E-selectin), chemokines (e.g., IL-8), acute phase proteins (e.g., serum amyloid A (SAA)), 
and inducible enzymes (e.g., inducible NO synthase (iNOS) and cyclooxygenase-2 ((COX-
2)), β-defensins and several TLR. These proteins are components of the innate immunity, 
some of them being essential for the migration of phagocytic leukocytes such as macrophages 
and neutrophils to the site of infection others facilitating activation/costimulation of 
leukocytes. Chemokines acts as chemoattractants on specific leukocytes. The cytokine TNF-α 
can itself activate NF-κB through some of the intracellular signaling proteins being part of the 
TLR signaling pathway. Expression of TNF-α therefore initiates a positive feedback loop 
(Liang et al., 2004). 
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NF-κB is not only involved in innate immunity but also function in adaptive immunity. NF-
κB in thymocytes of the thymus regulates transcription of target genes involved in maturation 
of T cells. Since NF-κB regulates expression of IL-2 in T cells, it also has a role in 
proliferation and differentiation of T cell. The RelA member of NF-κB regulates the 
transcription of major histocompatability complex class 1 (MHC class1) and CD40 in 
fibroblasts (Liang et al., 2004). MHC class 1 and 2 are transmembrane proteins that present 
antigens to T cells thereby activating those. CD40 is a transmembrane costimulatory protein 
that is also necessary for activation of T cell, but also in the activation of B cells by helper T 
cells (Alberts et al., 2002). Furthermore NFκB also seems to have a function in development 
of memory cells.       
6.12 TH1 or TH2 response 
Activation and differentiation of naïve Helper T cells require three types of signals. 
Stimulation or signal 1, which is mediated by T-cell receptor (TCR) interacting with antigen-
MHC class II complex. Costimulation or signal two is mediated by cluster of differentiation 
80 (CD80) or CD86 of DCs interacting with CD28 on naïve Helper T cells. (Corthay, 2006). 
The nature of the third signaling way called polarization is not fully understood. But seems to 
depend on both the nature of antigen-MHC class II complex, type of costimulation and type 
of cytokine produced by DCs (Janeway, 2005). The cytokine IL-12 produced by DCs 
stimulate the development of TH1 cells. TH1 and TH2 cells secrete different types of cytokines 
and thereby initiate two different kinds of responses (see figure 7). TH1 cells secrete mostly 
IFN-γ and TNF-α, which activates macrophages to eliminate the pathogens harboured within 
its phagosome. These cytokines also activate cytotoxic T cells to kill pathogen infected cells. 
In this manner TH1 cells mostly protects the host against intracellular pathogens. TH2 cells 
secrete IL-4, IL-5, IL-10 and IL-13. These cytokines stimulates B cells to secrete most types 
of antibodies and thereby protects the host against extracellular pathogens (Alberts et al., 
2002).  
 
DCs can also induce various regulatory T (Treg) cells. Treg cells can suppress both TH1 and 
TH2 response, either by direct cellular interaction or by secretion of the anti-inflammatory 
cytokines IL-10 and TGF-β (Guarner et al., 2006). It is believed that IBD patients lack this 
anti-inflammatory regulation and that an uncontrolled TH1 response cause’s the chronic 
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inflammation and tissue damage seen in both CD and UC. The hygiene hypothesis suggests 
that reduced exposure to relatively harmless microorganisms in modern society can be 
associated with a defective development of immunoregulatory pathways in IBD (Macpherson 
and Harris, 2004; Guarner et al., 2006). 
 
 
Figure 7 Decision-making in the adaptive immune system. Antigen-presenting DC cells take up foreign antigens 
and degrade them to immunologenic peptides that are presented to T-cells. These differentiate into T-helper-1 or 
T-helper-2 cells with different cytokines secretion. Certain DCs can induce regulatory T-cells, which via 
cytokines IL-10 and TGF-β can suppress both TH1 and TH2 response. Induction is indicated with green arrows, 
and suppression with red arrows (figure adapted from Guarner et al., 2006).  
 
6.13 Distinguishing commensals from pathogens 
One way of distinguishing commensals from pathogens is by compartmentalization of PRRs. 
TLR 3 and TLR7-9 are resident in endosome, TLR5 is located at the basolateral membrane 
while expression of TLR2 and TLR4 seems to be attenuated in intestinal epithelial cell. 
Finally NOD1 and NOD2 are located in the cytoplasma. This physically hinders commensal 
bacteria from adversely inducing immune response and facilitates response against invading 
pathogens. 
 
Pathogens differ genetically from commensals in their possession of pathogenecity genes 
often assembled in pathogenicity islands. Pathogenicity islands can be transferred from one 
bacterium to another by horizontal genetic transfer (transformation, conjugation and 
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transduction) and their genes encode virulence factors. Virulence factors are proteins such as 
adhesion molecules, toxins, enzymes and secretion systems that all aids the pathogen in 
invasion and colonization of intestinal tissue leading to local or systemic infection. Different 
adhesion molecules mediate the initial adhesion of the pathogen to the intestinal mucosa. Five 
secretion systems called type I-V secretion system acts in different manners to transfer 
virulence factors from the pathogen to the intestinal epithelia. Secretion usually occurs 
subsequently from adhesion. The secreted virulence factors often target epithelia actin 
filaments of the cytoskeleton thereby enabling to pathogen to move within or between host 
cells. Or even create cellular compartments within epithelia cells for pathogenic residence. 
Invasion of the intestinal epithelia usually occurs through the M cells of FAE. Pathogens 
generally apply one of two different strategies being either invasive or non-invasive. Invasive 
bacteria such as Salmonella and Shigella are characterized by the ability to invade epithelia 
and thrive in the hostile environment of Peyer’s patches and lymph nodes. Non-invasive 
bacteria inject virulence factors into epithelia cells but stay extracellular themselves.     
(Magalhaes et al., 2007) 
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7. Mechanisms of action of probiotics 
This chapter will present mechanisms suggested as essential factors in the beneficial effects of 
probiotics. The mechanisms will be divided into three categories: (1) Inhibiting microbial 
pathogens growth (2) Increasing epithelial barrier function (3) Modulating immune response 
of intestinal epithelia and mucosal immune cells.  
 
7.1 Inhibiting microbial pathogens growth. 
The simplest mechanism for beneficial probiotic action is by competing with the pathogens 
for nutrition and space, thereby preventing their colonization of the GI. In the pathogenesis of 
intestinal infections, preliminary steps include penetration through the mucus layer and the 
adhesion of the pathogenic bacteria to the epithelial cells in the gut. In theory, preventing this 
adhesion could constitute a therapeutic strategy.  
Pathogens attach to epithelial cells on a limited number of receptors situated on the cell 
surface. One of the principles of probiotic therapy is the occupation of these receptors by 
probiotic strains of bacteria preventing invasive pathogens from settling.    
 
• Boudeau et al., 2003 reported in an in vitro study the capacity of adhesion compared 
between a pathogenic strain LF82 of Escherichia coli (E. coli) and the non-pathogenic 
subspecies E. coli Nissle 1917. The non-pathogenic strain was shown to impair 
colonization of the pathogen species by forming a biofilm on the cell surface layer of 
the epithelial cells, thus occupying all adhesive space. The supposed mechanism 
explaining the dominance of E. coli Nissle 1917 was believed to be an adhesive factor 
with higher affinity to receptors on the epithelial cell surface (Boudeau et al., 2003). 
This may be a protective mechanism shared by other probiotic species. 
 
• Fujiwara et al., 1997 reported the existence of a 100 kDa protein produced by 
Bifidobacterium longum, that in vitro displayed an inhibitory effect on the binding of 
an E. coli strain (pb 176) to the glycolipid binding receptor, GA1. In 2000 the protein 
was tested on an enterocyte-like cell with equivalent results, suggesting that some of 
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the beneficial effects attributed to probiotics may arise from this mechanism (Fujiwara 
et al., 2001; Bai and Ouyang, 2006). 
 
• Shiba et al., reported that B. infantis 1222 inhibited the growth of the bacteroid B. 
vulgatus in co-culture and in the gut of gnotobiotic mice. Gut colonization with B. 
vulgatus increases the number of Peyer’s patches (PP) cells carrying PNA+(peanut 
agglutinin)/anti-κ+ phenotype, which represent plasma cell-like B cells, which 
increases the production of antibodies. B. Infantis 1222 protects the epithelial layer 
and PP from being invaded by bacteroids such as B. vulgatus by decreasing the 
number of cells carrying PNA+/ anti-κ+ phenotype in PP, thereby suppressing the 
antibody stimuli induced by B. vulgatus (Shiba et al., 2003). 
 
7.2. Increasing epithelial barrier function 
The intestinal tract is perpetually exposed to microorganisms of the lumen. The intestinal 
tissue posses different levels of physical barriers that prevent from constant infection by these 
microorganisms. The first line of barrier is constituted by the intestinal epithelial cell that 
produces mucus and glycocalyx which traps bacteria, which are subsequently eliminated by 
intestinal epistalsis and water hydrous flow. Microvilli present at the apical surface of 
epithelial cell create a hinder for attachment of bacteria. And most importantly are the firm 
joinment of epithelial cells by the transmembrane molecular complexes termed tight junctions 
(Magalhaes et al., 2007). Tight junctions forms sealing strands encircling epithelia cells and 
functioning as a selective permeability barrier occluding larger objects such as bacteria 
(Alberts et al., 2002). 
 
• Fermentating commensal bacteria produce short chain fatty acids such as butyrate (see 
section 8.6) Bordin et al. demonstrated that different types of cells (HeLa and 
fibroblasts) treated with sodium butyrate had increased expression of the tight junction 
components occludin, ZO-1, ZO-2 and cingulin. ZO-1 and ZO-2 acts as linkers 
between transmembrane components of tight junctions and actin proteins of the 
cytoskeleton. It was shown that the effect was mediated by sodium butyrate acting as 
an histone deacetylase  inhibitor (Bordin et al., 2004). Acetylation of histone faciliates 
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binding of transcription factors and promotes transcription (Alberts et al., 2002). 
Inhibition of a histone deacetylase therefore likewise promotes transcription.      
 
• Bruewer et al. demonstrated that pro-inflammatory cytokines IFN-γ and TNF-α 
compromise the epithelial barrier function. Elevated levels of cytokines were 
associated with internalisation of transmembrane proteins such as junction adhesion 
molecule 1 and occludin, involved in tight junction formation (Bruewer et al., 2003). 
The exact mechanism of how probiotic strains can lower the levels of IFN-γ and TNF-
α is not understood. However Yan and colleagues have in two studies shown that 
Lactobacillus rhamnosus GG (LGG) secretes proteins that inactivate cytokine-
activated pathways, initiated by IFN-γ and TNF-α. In the 2007 paper they reported 
isolating two proteins (p75 and p40) secreted from LGG (and L. casei 334, L. casei 
339), both having an inhibitory effect on TNF-induced apoptosis in intestinal 
epithelial cells but also enhancing the proliferation and survival of the latter due to the 
activation of Akt and inhibition of MAPK (p38). L. acidophilus was shown to have a 
similar effect, but required bacterial-epithelial cell contact for the effect (Yan and 
Polk, 2002; Yan et al., 2007). 
 
• Madsen et al. demonstrated that IL-10 gene-deficient mice treated with VSL#3 
resulted in improvement of the intestinal barrier function and reduction of cytokines 
IFN-γ and TNF-α. They also demonstrated VLS#3 preventing invasion of Salmonella 
Dublin in T84 monolayer cells. This was attributed to either improvement in barrier 
integrity or conversely by binding of probiotic bacteria to surface receptors to block S. 
dublin invasion (Madsen et al., 2001). 
 
 
7.3 Modulating immune response of intestinal epithelia and mucosal 
immune cells.  
Probiotics can modulate inflammatory response in intestinal epithelia and immune cells by 
interfering with proteins of signal cascades mainly TLR and NOD causing inflammation. 
Interference can occur at any level of signaling from receptors such as TLRs og NODs 
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through intracellular signaling proteins such as IκB to transcription factors such as NF-κB. 
Attenuation of these pathways can lead inhibited expression of pro-inflammatory molecules 
as cytokines and chemotaxins. In contrast activation of signal cascades can lead to increased 
expression of immunosupressive cytokines. A great number of publications addresses this 
issue, and only some examples will be given in the following of mechanisms.    
 
• Kelly et al., demonstrated that induction of inflammation in rat intestines by infection 
with Salmonella enterica Seravo enteriditis (S. enteriditis) could be attenuated by 
treatment with B. thetaiotaomicron. Rats challenged with S. enteriditis only showed 
extensive histological injury to crypts and villi followed by infection of lamina propia. 
Rats being administered with both S. enteriditis and B. thetaiotaomicron showed 
preserved intestinal structure although some infection was seen. They also 
demonstrated that the cell line Caco-2 (Human colonic adenocarcinoma cells) cultured 
with S. enteriditis only showed increased nuclear translocation of PPARγ concimitant 
with RelA (se section 6.9). In contrast Caco-2 cocultered with S. enteriditis and B. 
thetaiotaomicron promoted nuclear export of PPARγ and RelA. It is therefore 
proposed that presence of B. thetaiotaomicron in a PPARγ-dependent manner 
mediates attenuation of inflammation in rat intestine (Kelly et al., 2004).   
 
• Neish et al., reported that different nonvirulent Salmonella species can inhibit 
ubiquination of IκB hindering its degradation and thereby preventing subsequent 
nuclear translocation of NF-κB in human intestinal epithelia cells (Neish et al., 2000). 
 
• Rachmilewitz et al., reported that the beneficial effect of VSL#3 and E. coli (DH5α) is 
due to the mediating effect of their DNA, which has immunostimulatory activities 
depending on TLR9. TRL9 signaling plays an essential role in mediating the anti-
inflammatory effect of probiotics and suggests that viable probiotics are as effective as 
nonviable probiotics (γ-irradiated). This finding could play a role for infants and 
immunocompromised patients, because nonviable probiotics are safer to use due to the 
reduced risk of bacteraemia (Rachmilewitz et al., 2004). 
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• Katakura et al., has shown that TLR9 induced by bacterial DNA lead to MyD88 
activation, which again activated downstream DNA-dependent protein kinase (DNA-
PK). DNA-PK interacted with transcription factors IRF1 and IRF8 promoting 
expression of the immunosupressive type I interferon α and β (IFNα and IFNβ) 
(Katakura et al., 2005).   
 
• Rakoff-Nahoum et al., reported that TLRs often mediate signaling through MyD88 
dependent signal cascades (se section 6.7). The anti-inflammatory effect MyD88 has 
also been demonstrated by MyD88-deficient mice being more susceptible to DSS 
induced colitis than wild type mice (Rakoff-Nahoum et al., 2004).  
 
• Sturm et al., reported in a study demonstrated that E. coli Nissle 1917 could modulate 
cytokine expression, cell cycling and proliferation of peripheral blood T cells (PBC). 
PBCs are resident in the systemic circulation but are recruited to mucosa upon 
inflammation. Anti-CD3-stimulated PBCs treated with E. coli Nissle 1917 medium 
showed decreased expression of pro-inflammatory TNF-α, IL2, IFN-γ but increased 
expression of immunosupressive IL10. Cell cycle was inhibited by decreased 
expression of cyclin D1 and cyclin B2 and therefore restriction of T cell proliferation. 
In a parallel study it was shown that PBCs from TLR2 knockout mice treated with E. 
coli Nissle 1917 had normal cell cycle progression, whereas PBCs from wildtype mice 
had reduced cell cycle progression. It was therefore proposed that the inhibitory effect 
of E. coli Nissle 1917 on PBCs were TLR2-dependent. Since bacterial lipoproteins 
(BLP) demonstrated a inhibition of PBC mimicking that of E. coli Nissle 1917, it was 
suggested that E. coli Nissle 1917 exerted its effect by BLPs (Sturm et al., 2005). 
 
• Yan et al., reported that they isolated two proteins (p75 and p40) secreted from 
Lactobacillus rhamnosus GG (LGG), both having an inhibitory effect on TNF-
induced apoptosis in intestinal epithelial cells but also enhancing the proliferation and 
survival of the latter due to the activation of Akt and inhibition of MAPK (p38). Akt 
was activated bye 10-1000ng/mL of p75 and 1-100ng/mL of p40 in a dose-dependent 
manner. Also L casei 334, L casei 339 but not L acidophilus supernatants were able to 
promote Akt activation and prevent TNF-induced apoptosis (Yan et al., 2007). 
 40
 
• McCarthy et al., demonstrated, in a double blind, placebo controlled trial, that 
Bifidobacterium infantis 35624 and Lactobacillus salivarius 433118 had beneficial 
effects on colitis in IL-10 knockout mice. The improvement was a result of reduced 
levels of Th-1 pro-inflammatory cytokine (INF-γ, TNF-α and IL-12). In all groups the 
level of TGF-β (Th-3) was maintained.  B. infantis 35625 had a larger effect in 
reducing pro-inflammatory cytokine production than L. salivarius 433188 (McCarthy 
et al., 2003). 
 
• Delmasso et al., reported that S. boulardii treatment inhibits inflammation by 
decreasing the activation of NF-κB, reducing the level of cytokine expression of TNF-
α, IL-1β, IFN-γ and IL-6 in the colon of CD4+CD45RBhi transferred severe combined 
immunodeficiency (SCID) mice with developed colitis. S. boulardii produces af a 
small water soluble molecule called SAIF (Saccharomyces anti-inflammatory factor), 
which mediates the inhibition of NF-κB. This inhibition involves prevention of IκBα 
degradation (se section 6.7) and thereby hindering of nuclear transport of NF-κB 
(Sougioultzis et al., 2006). The beneficial effect of S. boulardii is dose-dependent and 
the probiotic must be ingested daily for maintaining the anti-inflammatory effect. S. 
boulardii limits the infiltration of TH1 cells into the inflamed colon. This effect is 
caused by accumulation of IFN-γ producing TH1 cells within the mesenteric lymph 
nodes. These findings suggest that S. boulardii may be used as a therapeutic tool in 
IBD (Dalmasso et al., 2006).  
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8. Probiotics species 
Probiotics have been defined as live microorganisms, which when administered in adequate 
amounts, confer a health benefit to the host. In order to assure safety for the patients a reliable 
probiotic product requires correct identification of the probiotic species applied and 
acknowledgement of the administered amounts. Since probiotics are not recognized as drugs 
but merely as nutritional supplements, no documentation regarding efficacy are required         
by the Food and Drug Administration (FDA) or national health agencies (Del Piano et al., 
2006). Probiotics species such as lactobacilli, E. coli Nissle 1917 and bifidobacteria are often 
isolated from healthy gut flora and has a history of lack of toxicity. A safe probiotic should 
not give rise to allergies and should not be able to colonize outside the GI. Probiotics should 
be either acid tolerant or be encapsulated to ensure their safe passage through the stomach 
(Del Piano et al., 2006). Some probiotic species are selected based on their inability to 
colonize the intestinal tract such as Saccharomyces boulardii and Trichuris suis (helminths 
from pigs).  
   
Animal and in vitro models are used to determine which probiotics (bacteria and yeast) have a 
beneficial influence on experimental colitis. The models are also utilized to improve the use 
and safety of probiotics, to detect side effects and to reveal the underlying mechanism of their 
beneficial effect. The most commonly used probiotics, which also are the organisms present 
in our selection of clinical trials, will be described below. All probiotics may posses all three 
mechanism of action, but mechanism of action will be listed according to our findings in 
section 7. Furthermore different subspecies of the same group may not posse’s alike 
mechanisms of action. This is likely due to subspecies differences in surface proteins and 
secreted metabolic products.    
 
8.1 Lactobacilli species 
Lactobacilli species are anaerobe gram-positive rods (1-9 μm). They are acid fermentative 
and therefore also acid tolerant, which allows their colonization of the entire GI including the 
duodenum at a low pH approaching 2. Lactobacilli only represent about 0.01% of the 
intestinal commensal flora, they are rarely pathogenic and mostly found in dairy products 
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(Shiba et al., 2003). Commonly used Lactobacilli species as probiotics include: L. 
acidophilus, L. bulgarucus, L. rhanmosus GG, L. johnsonii, L. lactis, L. plantarum, and L. 
reuteri.  
 
• Mechanism of action contributed to lactobacilli species are 7.2 Increasing epithelia 
barrier function and 7.3 Modulating immune response of intestinal epithelia and 
mucousal immune cells.  
8.2 Bifidobacteria species 
Bifidobacteria species are anaerobic gram-positive bacteria and inhabitants of a healthy 
human colon accounting for app. 10% of the commensal microflora (Shiba et al., 2003). They 
are bile and acid tolerant, and survive the passage through the GI.   
 
• Mechanism of action contributed to bifidobacteria is 7.1 Inhibiting microbial pathogen 
growth and 7.3 Modulating immune response of intestinal epithelia and mucousal 
immune cells. 
 
8.3 Escherichia coli Nissle 1917  
The strain is a non-pathogenic member of the gram-negative bacteria species E. coli. It was 
originally isolated during Word War I from a soldier who withstood a severe outbreak of 
diarrhoea (Boudeau et al., 2003) 
 
• Mechanism of action contributed to bifidobacteria is 7.1 Inhibiting microbial pathogen 
growth, 7.2 Increasing epithelia barrier function and 7.3 Modulating immune response 
of intestinal epithelia and mucosal immune cells. 
 
8.4 Saccharomyces boulardii 
S. boulardii is a non-pathogenic, non-systemic yeast, first isolated from lychee and 
mangosteen fruit in 1923. It is known to be beneficial in preventing and treating a variety of 
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diarrheal diseases by maintaining and restoring the natural flora in the large and small 
intestine. 
 
• Mechanism of action contributed to S. boulardii is 7.3 Modulating immune response 
of intestinal epithelia and mucousal immune cells. 
 
8.5 VSL#3 
VSL#3 is a probiotic cocktail containing viable lyophilized gram-positive bacteria of 4 strains 
of lactobacilli (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii ssp. bulgaricus), 3 
strains of bifidobacteria (B. longum. B. breve, and B. infantis) and one strain of Streptococus 
salivarius ssp. Thermophilus. 
 
• Since VSL#3 is a combination of several probiotics species the mechanism of action 
contributed to VSL#3 is 7.1 Inhibiting microbial pathogen growth, 7.2 Increasing 
epithelia barrier function and 7.3 Modulating immune response of intestinal epithelia 
and mucosal immune cells.  
8.6 Prebiotics 
Prebiotics are substances destined to promote growth and metabolism of the commensal 
bacteria flora. Most prebiotics are present as nondigested carbohydrates such as fructo-
oligosaccharides, inulin, psyllium or germinated barley extracts, which are all substances that 
support the populations of Lactobacilli and Bifidobacteria. Apart from improving the 
conditions of survival for these beneficial bacteria, one of the interesting potentials of 
prebiotic treatment lies in its stimulating effect on the production of short chain fatty acids 
such as butyrate. The term symbiotic defines the therapeutic assembly of probiotics and 
prebiotics, combining the beneficial properties of both methods. 
 
• Anti-inflammatory properties are also attributed to butyrate through inhibition of the 
binding activity of NF-kB to DNA in epithelial cells, thus reducing the production of 
proinflammatory cytokines such as IL-6 and IL-8 (Kanauchi et al., 1999). 
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• In accordance with these findings, Kanauchi et al., reports on basis of endoscopic 
observations that bacterial production of butyrate in the colon had a beneficial effect 
on mucosal damage in Ulcerative Colitis (Kanauchi et al., 2003). To this day however, 
the experimental data supporting the beneficial use of prebiotics is even less 
elucidated  than that of probiotics (Sartor, 2004). 
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9. Clinical studies 
 
We want to assess the clinical effectiveness of probiotics in the treatment of IBD (with focus 
on CD and UC). In order to do that, we searched the PubMed1 database in April 2007 for 
reports on clinical studies. 
 
9.1 Search methods for finding studies 
To locate relevant articles we used the search term “probiotic*” and in an attempt to find as 
many articles as possible we also added terms for specific organisms (since not all authors use 
the term “probiotics”): “trichuris*”, “lactobacillus*”, “saccharomyces*” and 
“escherichia*”. We then narrowed the search by adding search terms for the individual 
diseases: “ulcerativ*” or “crohn*”. The search was further refined by adding the search 
terms; “random*” and “NOT review”. So in an attempt to find articles reporting on 
randomized clinical trials using probiotics on ulcerative colitis, we would use the search 
string: “probiotic* OR trichuris* OR lactobacillus* OR saccharomyces* OR 
escherichia* AND ulcerativ* AND random* NOT review”. A few additional articles were 
found by manual search (i.e. we found them mentioned in other articles). 
 
9.2 Study selection 
In order to assess the relevance and quality of the resulting studies we rated them using the 
Jadad-scale (Jadad et al., 1996). The Jadad-scale is an attempt to create an instrument to 
evaluate clinical trials in an easy and unbiased way. Instead of judging the articles on whom 
the authors are, which institutions they are from or dazzling figures in the articles; the Jadad-
scale evaluate simple methodical parameters: whether the trial was properly randomized and 
blinded, and whether all enrolled patients are described – also the ones that drop out of the 
trial. We chose to use studies that scored 2 or more points on the scale (se Appendix B for 
more details about the Jadad-scale).      
                                                 
1 PubMed is a public database maintained by the National Center for Biotechnology Information (NCBI). It 
gives free access to the over 12 million abstracts in MEDLINE. The database can be accessed at: 
http://www.pubmed.gov.   
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9.3 Description of studies 
We found a total of 30 articles reporting on studies of probiotic treatment of IBD (16 on CD 
and 14 on UC). Not all trials fulfilled our selection criteria of 2 points on the Jadad-scale and 
some of them were duplicates describing the same studies. Below we list the trials that we 
chose to include in this analysis, with a short description and mention the excluded trials, with 
a short explanation of why they were not included. 
 
9.3.1 Crohn’s Disease 
Of the 16 reports six were excluded from the analysis. One study evaluated the effect of 
dietary yeast on CD and was not a probiotic intervention trial (Barclay et al., 1992). Another 
study tested the effect of VSL#3 on arthralgia in patients with IBD (Karimi et al., 2005). The 
third study was an un-blinded study containing both CD and UC patients (Zocco et al., 2003). 
Two were duplicate reports on an open label pilot study, without control group (Gupta et al., 
2000; Guandalini, 2002). The last excluded study was a derivative of an included study 
(Prantera and Scribano, 2002). The included reports are described below. (Best et al., 1976) 
  
Plein and Hotz 1993 
In this single centre, randomized, double-blind, placebo-controlled study 20 patients with 
mildly active CD were treated with Saccharomyces boulardii as a supplement to conventional 
treatment. All patients received 250 mg Saccharomyces boulardii three times a day for two 
weeks. Symptoms in the form of frequency of bowel movements and CDAI were compared 
before and after, and an improvement was registered (Bowel movements went from 5.0 ± 1.4 
to 4.1 ± 2.3 evacuations/day and CDAI1 went from 193 ± 32 to 168 ± 59). The 17 remaining 
patients were then allocated randomly into a placebo group of 7 patients and a treatment 
group of 10 patients continuing Saccharomyces boulardii for seven weeks. After 10 weeks the 
two groups were evaluated: the treatment group had a frequency of bowel movements of 3.3 ± 
1.2 evacuations/day and a CDAI of 107 ± 85. The placebo group had 4.6 ± 1.9 
evacuations/day and a CDAI of 180 ± 61. The amelioration of symptoms after the initial two 
weeks treatment with Saccharomyces boulardii was significant, but was largely due to 
                                                 
1 Crohn’s Disease activity index was suggested by Best et al., 1976 as a clinical index for CD. It uses a number 
of clinical and biochemical values to assess the disease. 
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improvement in frequency of bowel movements and to a lesser extent in CDAI. In the final 
comparison between treatment and placebo, the small number of subjects and large variations 
within the two groups rendered the result insignificant. No adverse effects were reported 
(Plein and Hotz, 1993). 
 
Malchow 1997 
In this single centre, randomized, double-blind, placebo-controlled study 28 patients with 
active CD (CDAI > 150) were treated with prednisolone (60 mg/day) + probiotics OR 
prednisolone + placebo1. The patients were randomly assigned into two groups; a group of 16 
patients who received prednisolone + Escherichia coli strain Nissle 1917 (two capsules of 100 
mg/day (2.5x1010 viable bacteria per capsule)) AND a control group of 12 patients who 
received prednisolone + placebo. Both groups were assessed 11 times during the one year 
study. The CDAI index was calculated and remission was defined as CDAI < 150. In the E. 
coli group 75% reached remission (12/16)2 and in the placebo group 91.7% (11/12). Of the 
patients that reached remission in the E. coli group 33.3% experienced relapse (4/12). In the 
placebo group it was 63.6% (7/11). However, because of the low number of patients these 
differences were not significant. No adverse effects were reported (Malchow, 1997). 
 
Guslandi 2000 
In this single centre, randomized, single-blind (investigator), controlled study 32 patients with 
CD in remission (CDAI < 150) received maintenance treatment either with mesalazine OR 
with reduced mesalazine and Saccharomyces boulardii. Patients had to be in remission 3 
month prior to the beginning of the study and had to be off immunosuppressant or steroid 
treatment for 3 month before entry. Patients were randomly allocated into two groups; a 
control group of 16 patients who received full dose of mesalazine (3g/day) AND a group of 
16 patients who received reduced mesalazine (2g/day) and Saccharomyces boulardii (1g/day). 
Both groups were assessed 3 times during the six month study; at entry and after 3 and 6 
months. CDAI was calculated and relapse was defined as CDAI > 150 with an increase of 100 
points over baseline for more than two weeks. In the Saccharomyces boulardii group 6.25% 
                                                 
1 When the patient reacted to prednisolone treatment the dose was tapered to 5 mg/day for one month prior to 
discontinuation. If symptoms worsened treatment with high concentrations was resumed. 
  
2 Two patients in the E. coli group were in remission at the beginning of the trial, but were included in the 
analysis on an intention-to-treat basis. Without these 85.7% in the E. coli group reached remission (12/14). 
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experienced relapse (1/16) and in the control group it was 37.5% (6/16). Because of the low 
number of patients this result was not significant. No adverse effects were reported (Guslandi 
et al., 2000). 
 
Rizzello 2000  
In this single centre, randomized, single-blind (investigator), controlled study 40 patients with 
surgically induced remission were treated with either an antibiotic followed by VSL#3 OR 
with mesalazine. Patients were randomly allocated into two groups; a treatment group of 20 
patients who received rifaximin (1.8 g/day) for 3 month followed by VSL#3 (6 g/day (3x1011 
viable bacteria/g)) for 9 month AND a control group of 20 patients who received mesalazine 
(4 g/day) for 12 month. Both groups were assessed by an independent physician after 3 and 
12 month in this one year study and relapse was defined endoscopically. After one year 20% 
(2 after 3 months and 2 after 12 months) in the antibiotic/VSL#3 group and 40% (8 after 3 
months) in the mesalazine group experienced relapse. This result was not statistically 
significant. No side effects were reported in the antibiotic/VSL#3 group, two patients in the 
mesalazine group experienced mild nausea (Rizzello et al., 2000).   
 
Prantera 2002  
In this single centre, randomized, double-blind, placebo-controlled pilot study 45 patients 
with surgically induced remission were treated with either Lactobacillus rhamnosus strain GG 
(LGG) OR placebo. Patients were excluded if they required antibiotic treatment for more than 
10 days after surgery, steroids for more than 30 days or were not able to start oral nutrition 
within 10 days after surgery. Patients were allocated into two groups; a treatment group of 23 
patients who received LGG (2.46g twice a day (1.2x1010 colony forming units/day)) AND a 
control group of 22 patients receiving placebo. Both groups were assessed after 13, 26, 39 and 
52 weeks of treatment in this one year study. Patients were assessed clinically and 
endoscopically. Clinical remission was defined as CDAI < 150 and endoscopic remission as < 
1 in the Rutgeert’s scoring system (Rutgeerts et al., 1990). At the end of the study 83.3% of 
the probiotic group was in clinical remission (15/23) and 89.4% in the placebo group (17/22). 
Of the patients in clinical remission 40.0% were in endoscopic remission in the probiotics 
group (6/15) and 64.7% in the placebo group (11/17). There was no significant benefit of the 
probiotic treatment. No trial related side effect were reported (Prantera et al., 2002). 
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Schultz 2004 
In this single centre, randomized, double-blind, placebo-controlled study 11 patients with 
moderate to active CD (CDAI 150 - 300) were treated with antibiotics and corticosteroids to 
induce remission and then with  Lactobacillus rhamnosus strain GG (LGG) OR placebo to 
maintain remission. All patients started on a 12 week tapered corticosteroid treatment, 
beginning with 60 mg/day. The first two week of the study they also received antibiotic 
treatment (ciprofloxacin 500mg twice a day and metronidazole 250 mg three times a day). 
Following the antibiotic treatment the patients were randomly allocated into two groups; a 
treatment group of 5 patients received LGG (2x109 colony forming units/day) AND a group 
of 6 patients received placebo. During the six months study patients were assessed after 2, 4, 
8, 12, 18 and 26 weeks. CDAI was calculated and relapse was defined as an increase in CDAI 
of > 100 points. After 6 months 80% of the patients in the LGG group sustained remission 
(4/5) and 83.3% in the placebo group (5/6). Of the patients that reached remission in the LGG 
group 50 % experienced relapse (2/4); this number was 60% in the placebo group (3/5). There 
was no significant difference between LGG and placebo treatment. Apart from mild bloating 
experienced by a few patients in both groups, no side effects were reported (Schultz et al., 
2004).     
 
Bousvaros 2005  
In this multi-centre, randomized, double-blind, placebo-controlled study 75 children (age 
range 5 - 21 yr) with CD in remission (Paediatric Crohn’s Disease Index (PCDAI) ≤ 10 
points) were treated with Lactobacillus rhamnosus strain GG (LGG) OR placebo to maintain 
remission. Patients were allowed treatment with aminosalicylates, 6-mercaptopurine, 
azathioprine and low-dose alternate day corticosteroids. Patients were randomly allocated into 
two groups; a treatment group of 39 patients received one capsule of LGG twice per day (1010 
bacteria and 295 mg inulin/capsule) AND a group of 36 patients received placebo. The study 
was designed as a 2 year study with examinations every 3 month (or at time of relapse). 
Relapse was defined as PCDAI > 30 points one time or as PCDAI > 15 points on any 2 
consecutive examinations more than 1 week apart. The study was stopped before time by the 
Data and Safety Monitoring Board overseeing the study, because of slow recruitment and lack 
of efficacy. At this point the median follow-up time for the LGG group was 9.8 months and 
11.7 for the placebo group. In the LGG group 39% experienced relapse (12/39) and in the 
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placebo group this number was 17% (6/36). This was not a significant difference. No adverse 
effects related to LGG were reported (Bousvaros et al., 2005).  
 
Marteau 2006  
In this multi-centre, randomized, double-blind, placebo-controlled study 98 patients with CD 
in remission after surgery received treatment with either Lactobacillus johnsonii LA1 (LA1) 
or placebo. No other treatment was allowed in the study. Patients were randomized into two 
groups; a treatment group of 48 patients receiving two packets per day of LA1 (2x109 colony 
forming units per packet) AND a control group of 50 patients receiving placebo. Patients 
were examined at inclusion and after 3 and 6 months, in this six months study. CDAI was 
calculated and clinical recurrence was defined as CDAI > 200 points. Ileocolonoscopy was 
performed after six months or in the case of clinical recurrence, and endoscopic recurrences 
were scored using the Rutgeert’s scoring system. Endoscopic recurrences were observed in 
49% of the patients in the LA1 group (21/43) and in the placebo group it was 64% (30/47). 
This was not a significant difference. No adverse effects related to the treatment were reported 
(Marteau et al., 2006).     
 
Van Gossum 2006  
In this multi-centre, randomized, double-blind, placebo-controlled study 70 patients with CD 
in remission after surgery were treated with either Lactobacillus johnsonii LA1 (LA1) or 
placebo. No other medication was allowed during the study. After surgery patients were 
randomly allocated into two groups: 34 patients received LA1 (1010 colony forming units/day) 
AND 36 patients received an identical placebo. The patients were examined endoscopically 
after 12 weeks or on relapse, with relapse defined as CDAI > 150 with an increase of 70 
points or higher over base line. En endoscopic recurrences were scored using the Rutgeert’s 
scoring system. On an intention-to-treat analysis the percentage of patients with severe 
recurrences were 21% in the LA1 group (6/28) and 15% in the placebo group (4/27). There 
was no significant benefit of the treatment. No adverse effect were reported (Van Gossum et 
al., 2006). 
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Chermesh 2007 
In this multi-centre, randomized, double-blind, placebo-controlled study 30 patients with CD 
in remission after surgery were treated with either Synbiotic 20001 or placebo. The patients 
were randomized in a 2:1 ratio to receive either one daily dose of Synbiotic 2000 (n = 20) OR 
placebo (n = 10). The study was planned to run over 24 months. Patients were assessed 
endoscopically (Rutgeert’s scoring system), clinically (bowel movements, abdominal pain 
and weight) and by laboratory tests (complete blood count, C-reactive protein, haemoglobin 
and albumin). Only nine patients completed the study; seven from the treatment group and 
two from the placebo group. From the endoscopic, clinical and laboratory data collected 
underway the researchers concluded that was no significant benefit from the treatment with 
Synbiotic 2000 in preventing post surgical recurrence of CD. Reasons for the 21 withdrawal 
were: self-withdrawal (8), exacerbation (7), arthritis and arthralgia (2), pregnancy (2), fistula 
(1) and postoperative complications (1). Apparently the withdrawals were not related to the 
treatment (Chermesh et al., 2007)     
 
9.4.1 Ulcerative colitis 
Seven of the fourteen reports were excluded from the analysis for various reasons. One study, 
which also came up in the CD search was not an intervention trial (Karimi et al., 2005). Three 
of the trials did not include a control group (Venturi et al., 1999; Guslandi et al., 2003; 
Bibiloni et al., 2005). Three studies was not blinded (Ishikawa et al., 2003; Tursi et al., 2004; 
Zocco et al., 2006) and the last excluded study was a duplicate report on an included trial 
(Macfarlane et al., 2005). The included trials are described below. 
 
Kruis 1997 
In this multi-centre, randomized, double-blind, double-dummy controlled study 120 patients 
with UC in remission (defined as CAI ≤ 4)2 were treated with E. coli Nissle 1917 or with 
mesalazine. No other treatments were allowed during the 12 week study period. 17 patients 
                                                 
1 Synbiotic 2000 is a mixture of probiotics and prebiotics. One daily dose in the study contained 4 lactic bacteria: 
1010 pedacoccus pentoseceus, 1010 Lactobacillus raffinolactis, 1010 Lactobacillus paracasei ssp. Paracasei 19 
and 1010 Lactobacillus plantarum 2362; and the 4 prebiotics 2.5 g β-glucans, 2.5 g inulin, 2.5 g pectin and 2.5 g 
resistant starch. 
 
2 Clinical activity index as defined by Rachmilewitz, 1989. The index rates clinical occurrences such as number 
of stools per week, blood in stool and abdominal pain/cramps. 
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were excluded before the beginning of the trial, but after randomization, because of CAI ≥ 4. 
The treatment group (n=50) received 200 mg/day of E. coli Nissle 1917 (5x1010 cfu/day) plus 
a mesalazine placebo. The control group (n=53) received 500 mg mesalazine three times a 
day and a placebo indistinguishable from the E. coli preparation. CAI was calculated at weeks 
0, 2, 4, 8 and 12. Remission was defined as CAI ≥ 4. In the treatment group 16.0% (8/50) 
experienced relapse; in the control group it was 11.3% (6/53). There was no statistically 
significant difference between the two groups. No adverse effects were reported (Kruis et al., 
1997). (Rachmilewitz, 1989). 
 
Rembacken 1999 
In this single-centre, randomized, double-blind, double-dummy controlled study 116 patients 
with active UC were treated with E. coli Nissle 1917 or with mesalazine. Remission was 
achieved by treatment with prednisolone for maximum 12 weeks (30 or 60 mg/day depending 
on severity of symptoms). At remission 57 patients were randomized to receive 400 mg/day 
of E. coli Nissle 1917 (5x1010 cfu/day) plus a mesalazine placebo. The 59 patients in the 
control group received 800 mg mesalazine three times a day and an E. coli placebo. Patients 
were reviewed monthly by their clinical symptoms and in the case of relapse by 
sigmoidoscopy (to confirm relapse).  39 patients in E. coli group reached remission (68%) and 
in the mesalazine group it was 44 (75%). In the E. coli group 26 (67%) patients experienced 
relapse before the end of the 12 month study. In the mesalazine group it was 32 patients 
(73%). These were statically comparable results. No adverse effects were reported 
(Rembacken et al., 1999).  
 
Kruis 2004 
In this multi-centre, randomized, double-blind, double-dummy controlled study 327 patients 
with UC in remission (defined as CAI ≤ 4)1 were treated with E. coli Nissle 1917 or with 
mesalazine. Patients were randomly allocated into two groups: a control group with 165 
patients receiving 500 mg mesalazine three times a day plus a E. coli placebo AND a group of 
162 patients who received 200 mg/day of E. coli Nissle 1917 (5x1010 cfu/day) plus a 
mesalazine placebo. The trial lasted 12 month and patients were assessed after 1,2,3,6 and 9 
                                                 
 
1 Clinical activity index as defined by Rachmilewitz, 1989. The index rates clinical occurrences such as number 
of stools per week, blood in stool and abdominal pain/cramps. 
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months and CAI was calculated. Relapse was defined as CAI ≥ 4 or an increase in CAI of 
more than 3 points. Patients were also evaluated endoscopically1 to confirm relapse. 110 
patients in the E. coli group and 112 in the mesalazine group completed the study. 36.4 
patients in the E. coli group experienced relapse (40/110) compared with 33.9% in the 
mesalazine group (38/112). This was significantly equivalent. No adverse effects were 
reported (Kruis et al., 2004). 
 
Cui 2004 
In this single-centre, randomized, single-blind, placebo-controlled study, thirty patients with 
UC in remission received maintenance treatment with BIFICO (Entreococci, Bifidobacteria 
and Lactobacilli) or with a placebo. Remission was induced by treatment with a combination 
of sulphasalazine and glucocorticoids. When in remission the patients were randomly 
allocated into two groups: a treatment group of 15 patients who received 1.26 g/day of 
BIFICO and a control group of 15 patients who received an identical placebo (starch). The 
patients were assessed clinically and endoscopically after 2 weeks and at the end of the 8 
week study (or at relapse). Biopsy samples were taken and analysed for expression levels of 
NF-κB and IL-10. Three patients in the BIFICO group experienced relapse (20%) compared 
with 14 (93.3%) in the placebo group. This was a significant difference. It was also shown 
that the level of NF-κB mRNA was significantly decreased in the BIFICO group and that the 
level of IL-10 was elevated compared with the control group. No adverse effects were 
reported (Cui et al., 2004). 
 
Kato 2004 
In this multi-centre, randomized, double-blind, placebo-controlled study twenty patients with 
mild to moderate active UC were treated with bifidobacteria-fermented milk (BFM) or with a 
similar placebo, both in addition to conventional treatment (3-4 g/day of salazosulphapyridine 
or 2250-3000 mg/day of mesalazine).  Patients were randomly allocated into two groups: a 
treatment group who received 100 mL/day of BFM and a placebo group who received 100 
mL/day of a similar placebo. Patients were assessed at week 4, 8 and 12 in this three month 
study. The patients were evaluated clinically and endoscopically. At the end of the study the 
CAI score in the BFM group had decreased from 7.9 ± 0.8 to 3.7 ± 0.4 compared to the 
                                                 
1 Endoscopic indicators were: granularity, vascular pattern, vulnerability of mucosa and mucosal damage.  
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placebo group that went from 7.9 ± 0.6 to 5.8 ± 0.8. This was a significant difference. The 
endoscopically score in the BFM group went from 4.4 ± 0.3 to 3.1 ± 0.3 compared to the 
placebo group that went from 3.6 ± 0.3 to 3.0 ± 0.4. No adverse effects were reported (Kato et 
al., 2004). 
 
Furrie 2005 
In this multi-centre, randomized, double-blind, placebo-controlled study eighteen patients 
with active UC were treated with a probiotic (Bifidobacterium longum) and a prebiotic 
(Synergy 1)1 OR a placebo, for a period of one month. No other treatment was allowed. 
Patients were randomly allocated into two groups: a treatment group that received 2x1011 
viable Bifidobacterium longum in a capsule and a sachet with 6 g of synergy 1 and a placebo 
group who received similar placebos. The patients were assessed at the beginning of the study 
and after one month. Patients were scored clinically and endoscopically and biopsy samples 
were taken for mRNA analysis. The clinical scores were not significantly different between 
the two groups: the synbiotic group started at 5.6 ± 3.7 and ended at 5.3 ± 3.4. The placebo 
group started at 4.9 ± 3.2 and ended at 3.1 ± 2.5. The endoscopic score in the synbiotic group 
went from 4.5 ± 1.4 to 3.1 ± 2.5 compared with the placebo group that went from 2.6 ± 2.1 to 
3.2 ± 2.2. This was not significant either, probably because of the low number of patients. 
However the mRNA levels of defensins 2, 3 and 4 were significantly reduced in the synbiotic 
group as compared to the placebo group and the mRNA levels of pro-inflammatory cytokines 
TNF-α and IL-1 were also significantly lower in the synbiotic group. No adverse effects were 
reported (Furrie et al., 2005). 
 
Summers 2005 
In this single-centre, randomized, double-blind, placebo-controlled study 54 patients with 
active UC (defined by UCAI ≥ 4)2 were treated with ova from the pig helminth Trichuris suis 
or with a placebo. Patients were allowed to continue conventional treatment such as 
mesalazine or prednisolone (< 25 mg/day) if the treatment had been given for more than 8 
weeks prior to the start of the study. Patients were randomly allocated into two groups: a 
                                                 
1 Synergy 1 is a fructo-oligosaccharide/inulin mix designed to stimulate the probiotic bacteria. 
 
2 Ulcerative colitis activity index (UCAI) is a clinical index described by Sutherland et al., 1987. It indexes 4 
variables: stool frequency, severity of bleeding, mucosal appearance and the physician’s overall assessment of 
the disease activity. 
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treatment group of 30 patients who received 2500 T. suis ova every second week for 12 weeks 
or a placebo group of 24 patients who received a placebo. The patients UCAI were calculated 
at 0, 6 and 12 weeks. In the ova treatment group 13 of 30 patients (43.3%) experienced a 
decrease in UCAI compared to 4 of 24 patients in the placebo group (16.7%). This was a 
significant difference. However the difference in the proportion of patients who achieved 
remission (UCAI ≤ 2) was not significant. No adverse effects from the treatment were 
reported (Summers et al., 2005). (Sutherland et al., 1987) 
 
9.5 Analysis   
From the data presented in the selected clinical studies we will address the following issues: 
 
• Are some types or species of probiotics more efficient in the treatment of CD and 
UC? 
• Are combinations of several strains of probiotics more efficient than single strains 
treatment? 
• Are large doses of probiotics more efficient than low doses?   
 
9.5.1 Clinical studies with Crohn’s Disease  
The selected clinical studies with CD are listed in table 2. The studies are ordered after 
probiotic species – with the lowest concentration first.  
 
From the clinical data we conclude that LGG, LA1 and Synbiotic 2000 have no efficacy in 
treatment of CD with the administered doses. The ten-fold difference in doses in the LGG and 
LA1 studies did not show any visible difference. VSL#3 that also contains lactobacilli species 
showed some efficacy (though not significant) but because of the experimental design it was 
not possible to determine if this was due to the initial antibiotic treatment or the following 
probiotic treatment. E. coli Nissle 1917 was more efficient than placebo in one small study. S. 
boulardii also showed some efficacy in two studies with almost similar doses.  
The efficacy for these last three studies were not significant because of the low number of 
subjects enrolled, this was a general problem in all the studies with CD. None of the probiotic 
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species or cocktails showed significant efficacy as compared to placebo/Mesalazine1 in 
obtaining remission or maintaining remission. It therefore seems that neither the probiotic 
strains nor concentrations used affect the mechanisms causing CD. Conclusion: from these 
data probiotics cannot be recommended as clinical treatment for CD. (Akobeng and 
Gardener, 2005) 
 
Study Size 
(n) 
Duration 
(weeks) 
Probiotic Control Result 
Plein and Hotz, 1993 20 10 S. boulardii 
(750 mg/day) 
Placebo + 
Guslandi et al., 2000 32 26 S. boulardii 
(1000 mg/day) 
Mesalazine + 
Malchow, 1997 28 52 E. coli Nissle 1917 
(5x1010 cfu/day) 
Placebo + 
Rizzello et al., 2000 40 52 VSL#3 
(3x1011 cfu/day) 
Mesalazine + 
Schultz et al., 2004 11 26 LGG 
(2x109 cfu/day) 
Placebo ÷ 
Pranterra et al., 2002 45 52 LGG 
(1.2x1010 cfu/day) 
Placebo ÷ 
Bousvarus et al., 2005 76 40* LGG 
(2x1010 cfu/day) 
Placebo ÷ 
Marteau et al., 2006 98 26 LA1 
(2x109 cfu/day) 
Placebo ÷ 
Van Gossum et al., 2006 70 12 LA1 
(1010 cfu/day) 
Placebo ÷ 
Chermesh et al., 2007 30 104 Synbiotic 2000 
(4x1010 cfu/day) 
Placebo ÷ 
Table 2 Clinical studies with Crohn's disease. Cfu: colony forming units. Explanation to the results: ÷ means 
same as placebo/mesalazine; + means better than placebo/mesalazine – but not significantly better. *Terminated 
ahead of time 40 weeks was the average treatment time.  
 
                                                 
1 Mesalazine has no significant effect on CD (Akobeng and Gardener, 2005). 
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9.5.2 Clinical studies with Ulcerative colitis. 
The selected clinical studies with UC are listed in table 3. The studies are ordered after 
probiotic species – with the lowest concentration first.  
 
Study Size 
(n) 
Duration 
(weeks) 
Probiotic Control Result 
Kruiz et al., 1997 120 10 E. coli Nissle 1917 
(5x1010 cfu/day) 
Mesalazine ++ 
Kruiz et al., 2004 327 52 E. coli Nissle 1917 
(5x1010 cfu/day) 
Mesalazine ++ 
Rembacken et al., 
1999 
116 52 E. coli Nissle 1917 
(10x1010 cfu/day) 
Mesalazine ++ 
Cui et al., 2004 30 8 BIFICO 
(1.26 g/day) 
Placebo ++ 
Kato et al., 2004 20 12 BFM 
(1010 cfu/day) 
Placebo ++ 
Furrie et al.,  2005 
 
18 4 B.  longum 
(2x1011 CFU/day) 
Placebo + 
Summers et al., 
2005 
54 40 Trichuris suis 
(2500 ova/day) 
Placebo ++ 
Table 3 Clinical studies with ulcerative colitis. Cfu: colony forming units. Explanation to the results: + means 
better than placebo – but not significantly better; ++ means significantly better than placebo or same as 
mesalazine. 
 
There were three studies with E. coli Nissle 1917 with a total of 563 subjects. The doses were 
comparable and all three studies the control group received treatment with Mesalazine. 
Therefore we conclude that E. coli Nissle 1917 was comparable to Mesalazine in efficacy. 
Two minor studies compared BIFICO and BFM to placebo, concluded that they both were 
significantly better than placebo in maintaining remission (BIFICO) or as a supplement to 
conventional treatment (BFM). The combination of VSL#3 and low-dose Balsalazide was 
compared to normal dose of either Balsalazide or Masalazide alone. VSL#3/Balsalazide 
showed the same efficacy as the single standard treatments. Trichuris suis was significantly 
better than placebo treatment in lowering the UCDAI index in patients with active colitis, but 
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not in obtaining remission. LGG showed better efficacy in prolonging the remission period 
for patient with UC than patients receiving Mesalazine alone.  
 
It seems that probiotics is better in maintaining and prolonging remission than to obtain 
remission in UC patients, but unlike for CD the efficacy in the former was significantly better 
than placebo and the same as standard treatments such as Mesalazine. Conclusion: this 
indicates that probiotics can be used as a valid alternative or supplement to Mesalazine 
in preventing relapse of UC. 
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10. Discussion 
 
The mechanisms of action of probiotics have mainly been elucidated though laboratory 
experiments and to a lesser extent though clinical studies. In the following we will attempt a 
synthesis of the theory and the clinical studies. We will take offset in the three main groups of 
probiotic mechanisms as described in chapter 7. 
  
1. Inhibiting microbial pathogens’ growth. 
Even though no specific bacterial species have been associated with CD or UC; it is known 
that the bacterial flora of IBD patients is altered compared to normal intestinal flora. Adherent 
and intramucosal bacteria especially E. coli, Bacteroides ssp. and Enterobacterium ssp. were 
elevated in patients with active IBD. In CD the level of Bifidobacteria were found to be 
decreased (Madsen, 2001). Therefore it is reasonable to assume that supplementing the 
intestinal microflora with non-pathogenic strains of these species, and thereby out-competing 
the pathogenic bacteria of nutrients can correct the imbalance. This can be accomplished in 
two manners, either by supplementing a specific antagonist to a suspected pathogen for 
example non-invasive E. coli Nissle 1917 against pathogenic E. coli bacteria capable of 
invading the mucus layer and adhering to the epithelial cells. Another strategy is to add a 
general non-pathogenic bacterium like lactobacilli that survive passage through the stomach 
and can colonize the entire length of the intestine (not like E. coli that mainly colonizes the 
colon). The eukaryote S. boulardii is also believed to be able to bind adherent pathogens to its 
surface and thereby preventing them from adhering to endothelial cells (Plein and Hotz, 
1993). 
 
It is also known that mutations in CARD15 (NOD2) are associated with CD in the ileum. 
CARD15 is believed to be involved in production of defensins in Paneth cells. CD patients 
with CARD15 mutations are known to have higher concentrations of luminal bacteria 
especially in crypts (Sartor, 2006). Probiotics secreting substances with similar effect as 
defensins could therefore possibly compensate for this deficiency. E. coli Nissle 1917 
possibly has a such effect by secreting bacteriocins or microcins and thereby inhibiting other 
bacteria (Rembacken et al., 1999). 
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2. Increasing epithelial barrier function. 
The barrier function of the GI is essential in protecting the gut from pathogens. Interaction 
between the commensal bacteria and the immune system takes place only in designated places 
– such as Peyer’s patches. The epithelial cells lining the gut are protected from the microflora 
by the mucosal layer (only certain pathogens are able to penetrate and invade the mucosal 
layer). If the mucus layer is compromised the second line of defence – tight junctions between 
the epithelial cells - will protect the lamina propia from invasion by preventing pathogens 
from passing via paracellular transport. Studies have shown that expression of tight junction 
proteins can be upregulated by secreted metabolites or direct contact with commensal 
bacteria. Bordin et al., have demonstrated that butyrate secreting bifidobacteria and 
lactobacilli can stimulate formation of tight junctions (Bordin et al., 2004). Bruewer et al., 
found that LGG secreted proteins (p75 and p40) could impede internalization of tight junction 
proteins. This effect was probably caused by countering elevated levels of proinflammatory 
cytokines TNF-α and INF-γ (Bruewer et al., 2003).     
 
3. Modulating immune response of intestinal epithelia and mucosal immune cells. 
It has been shown that a normal microflora is essential for the development of the Gut-
associated lymphoid tissue (GALT) mainly Peyer’s patches and lymphoid tissue. Germ-free 
mice show immunological abnormalities such as poorly formed B- and T-cell zones in 
Peyer’s patches, lymph nodes and spleen. The gene expression profile of epithelial cells is 
also different compared to normal mice (Macpherson and Harris, 2004). This indicates that 
the mucosal immune system needs to be exposed to microorganisms in order to develop 
normally. The hygiene hypothesis suggests that certain microorganisms or harmless helminths 
up through evolution have assumed this role of activating our immune system. This would 
explain the rise in autoimmune diseases (IBD, Type 1 diabetes and allergies) in the Western 
world, but not in third world countries where infection with microorganisms and helminths 
are common. This would explain why probiotics, at least in UC, seems to have an anti-
inflammatory effect. By suppressing the destructive TH1 response (characterizing both CD 
and UC) probiotics can prevent tissue damage. This can be achieved by inducing anti-
inflammatory cytokines such as IL-10 and TGF-β (Guarner et al., 2006). Animal models also 
show a down-regulation of pro-inflammatory cytokines such as IFN-γ and TNF-α after 
treatment with probiotics (McCarthy et al., 2003; Sturm et al., 2005; Dalmasso et al., 2006). 
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This indicates that non-pathogenic microorganisms (e.g. Lactobacilli, Bifidobacteria and 
helminth) are perceived as “friendly” by the immune system and therefore activate Treg cells 
secreting IL-10 and TGF-β and thereby down-regulates the TH1 response (Guarner et al., 
2006). If further indicates that probiotics can help in obtaining homeostasis in the mucosal 
immunesystem, thereby controlling the inflammatory process of IBD. This also correlates 
with the efficacy of TNF-α antibodies in treatment of both CD and UC (Waller et al., 2005). 
 
Evaluating the etiology of UC and CD 
Experimental colitis in model animals is often used to simulate CD or UC. However, it does 
not show the same etiology as CD and UC. In experimental colitis the inflammation is 
induced artificially by substances such as dextran sulphate sodium (DSS) or 2,4,6-
trinitrobenzenesulphonic acid (TNB) and when the substance is discontinued the symptoms 
disappear. Similarly the bacterial flora of animals (such as mice and rats) differs significantly 
from humans. This makes it difficult to extrapolate from animal experiments to humans and 
possibly explains why the promising results in animal models are difficult to reproduce in the 
clinical studies. It would therefore be useful with more research in probiotic action 
mechanisms with experiments in human models, either cell cultures or in vivo when possible.   
   
We saw in the clinical trials that probiotics were beneficial against UC but not CD, at least not 
significantly. The reason for this could be the genetic factors in IBD. Several gene defects 
have been associated with CD, whereas only a few have been connected to UC. Even though 
genetic factors only partially explain the diseases it might play a significant role in CD. This 
would also explain why CD is more refractory to treatment (both conventional and with 
probiotics) and more often requires surgery. UC secondly is confined to the colon, which has 
a richer microflora; it would therefore be plausible that alterations of the microflora with 
probiotics would be more efficient in UC as compared to CD, which can be located over the 
entire gut.  
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11. Conclusion and future prospects 
 
Our literature study showed that several probiotics (E. coli Nissle 1917, BIFICO, BFM, 
VSL#3, Trichuris suis and LGG) showed efficacy in maintaining remission in UC, but not in 
CD. This is probably due to the different localization of the inflammation and maybe different 
etiology. Numerous sources suggest that the genetic factor plays a larger role in CD than UC 
and that this is one of the reasons for the poor results in the clinical trials with probiotics. We 
believe that probiotic species used in clinical trials are well chosen but we suggest that the 
probiotic treatment in IBD should be given before the outbreak of the disease. Possibly by 
treating children genetically predisposed for IBD at an early age, preferably neonatal. This 
will allow the immune system to develop the necessary mechanisms to control the immune 
response and avoid the uncontrolled TH1 response characteristic for IBD. We therefore 
recommend further investigation in genetic markers for IBD, in order to be able to offer 
genetic screening of babies with a known family history of IBD. 
 
Apart from modulating the immune response of intestinal epithelia and mucosal immune 
cells, probiotics have also been shown to inhibit growth of microbial pathogens. This effect 
has been associated with E. coli Nissle 1917 and with S. boulardii, which were the only two 
organisms showing an effect against CD in clinical trials, but because of the low number of 
subjects they were not shown to be significantly better than placebo. E. coli Nissle 1917 also 
showed efficacy in treatment of UC. Probiotics (Lactobacilli and Bifidobacteria) can increase 
the barrier function of the epithelial cells, thereby protecting from invading pathogens. This 
indicates that probiotics also can play a role in treatment of developed IBD, especially UC. 
 
Our recommendation for the future is to pursue the possibility of neonatal treatment with 
probiotics. We also believe that more human trials are needed in order to understand the 
mechanisms of action of probiotics. The possibility of combining pre- and probiotic agents in 
one treatment (synbiotics) seems appealing, as the prebiotic moiety could be integrated in the 
patient’s diet while the administration of the probiotics could be reduced in frequency due to 
the prolonged survival of the beneficial bacteria. Since probiotics seem to be safe their use in 
treatment of IBD should be further investigated. 
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12. Glossary 
Blinded: When one or more parties (subject, investigator and assessor) to the study are kept 
unaware of which treatment each subject is receiving until the end of the study. 
 
Controlled study: A study in which a treatment group, receiving the investigational drug, is 
compared with a similar control group. The control group may receive no treatment, standard 
treatment or a placebo. 
 
Double-blind: A study in which both subject and investigator are unaware of which treatment 
each subject is receiving until the end of the study.  
 
Double-dummy: A technique for retaining the blind in a clinical study, when the two 
treatments cannot be made identical (for example pills versus injections). Supplies are 
prepared for treatment A (active and indistinguishable placebo) and for treatment B (active 
and indistinguishable placebo). Subjects then take two sets of treatment; either A (active) and 
B (placebo) or A (placebo) and B (active). 
 
Intention-to-treat: The principle that a subject that has been allocated to a group (treatment 
or control) should be followed up, assessed and analyzed as a member of that group, even if 
he/she discontinues the treatment. 
 
Open label study: A study in which both subject and investigator know what treatment the 
subject is receiving. 
 
Pilot study: A pilot study is a small-scale study used to obtain information, and work out the 
logistics and management, deemed necessary for further large scale clinical studies. 
 
Placebo-controlled: A study in which the treatment group, receiving the investigational drug, 
is compared with a similar control group receiving a placebo. The placebo should be an 
inactive product indistinguishable from the active drug. 
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Randomized: When the subjects in a study are allocated into treatment group(s) and control 
group in an unpredictable way; to avoid allocation of similar subjects to the same group. 
 
Single-blind: A study in which one party, either the subject or the investigator, is kept 
unaware of which treatment is administered to the subject until the end of the study. 
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Appendix A: Anatomy of the small and large intestine. 
 
The small intestine 
The small intestine consists of the duodenum, jejunum and ileum. The small intestine is about 
6 m long where the duodenum is about 25 cm long, the jejunum is about 2.5 m long and the 
ileum is about 3.5 m. In the Duodenum immediately after the stomach, the low pH of about 4 
restricts the bacterial flora; only acid tolerant bacteria such as lactobacilli and enterococci are 
the main inhabitants. As the pH is gradually raised, the microflora becomes more diverse.     
  
 
 
Figure A.1 The listed bacteria are the predominant species, in the small intestine. 
 
The surface area of the duodenum is increased about 600-fold caused by circular fold in the 
mucosa and submucosa and by villus in the mucosa with is coved by microvilli. The jejunum 
and ileum are similar in structure expect that a gradual decrease occur in the number of 
circular folds and villi. There is also seen a gradual decrease in the diameter of the small 
intestine and the thickness of the intestinal wall.  
 
The mucosal lining of the small intestine is simple columnar epithelium. Four cell types are 
found in the mucosa (1) absorptive cells produce digestive enzymes and absorb digested food 
(2) goblet cells produce protective mucus (3) granular cells (Paneth’s cells) protect the 
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intestinal epithelium from bacteria and (4) endocrine cells produce regulatory hormones. In 
the mucosa and submucosa of the ileum there are found numerous lymphatic nodules called 
Peyer’s patches.   
 
The large intestine 
The large intestine consists of the cecum, colon, rectum and anal canal. The cecum forms a 
blind sac at the transition of the small and large intestine. The colon with is about 1.5-1.8 m 
long is divided in the ascending colon, transverse colon, descending colon and sigmoid colon. 
In the colon were the pH is close to 7; the largest number and diversity of bacteria exists. In 
total about 500-1000 different species are present in the GI, in a variety of numbers; the major 
species are listed in figure A.2. 
 
 
 
 
Figure A.2 The major bacterial species of the large intestine. 
 
The mucosal lining of the large intestine is simple columnar epithelium and consists of 
numerous straight tubular glands called crypts. Three cell types are found in the mucosa (1) 
absorptive cells (2) goblet cells and (3) granular cells. The goblet cells are dominated in 
number. The mucus produced by goblet cells lubricates and protect the wall of the colon and 
helps faecal matter stick together. 
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Appendix B: The Jadad-scale. 
 
Grading clinical trials using the Jadad-scale is performed by answering the following three 
questions and scoring them as described: 
 
1. Is the study described as randomized (this includes the use of words such as 
randomly, random, and randomization)? 
 
2. Is the study described as double blind? 
 
3. Is there a description of withdrawals and dropouts? 
 
 
Scoring the items: 
Either give a score of 1 point for each “yes” or 0 points for each “no”. There are no in-
betweens marks. 
 
 
Give 1 additional point if: For question 1, the method to generate the sequence 
of randomization was described and it was 
appropriate (table of random numbers, computer 
generated, etc.) 
 
And/or: If for question 2 the method of double blinding was 
described and it was appropriate (identical 
placebo, active placebo, etc.) 
 
Deduct 1 point if: For question 1, the method to generate the sequence 
of randomization was described and it was 
inappropriate (patients were allocated alternately, 
or according to date of birth, hospital number, etc.) 
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And/or: For question 2, the study was described as double 
blind but the method of blinding was inappropriate 
(e.g. comparison of tablet vs. injection with no 
double dummy) 
 
 
Guidelines for assessment: 
 
1. Randomization 
 A method to generate the sequence of randomization will be regarded as appropriate if it 
allowed each study participant to have the same chance of receiving each intervention and the 
investigators could not predict, which treatment was next. Methods of allocation using date of 
birth, date of admission, hospital numbers, or alternation should not be regarded as 
appropriate. 
 
2. Double blinding 
A study must be regarded as double blinded if the word “double blind” is used. The method 
will be regarded as appropriate if it is stated that neither the person doing the assessment nor 
the study participant could identify the intervention being assessed, or if in the absence of 
such a statement the use of active placebos, identical placebos, or dummies is mentioned. 
 
3. Withdrawals and dropouts 
Participants who were included in the study but did not complete the observation period or 
who were not included in the analysis must bed described. The number and the reasons for 
withdrawal in each group must be stated. If there were no withdrawals, it should be stated in 
the article. If there is no statement on withdrawals, this item must be given no points. 
 
   
 
